Abstract
Although the advent of focused and therefore superior immunosuppressive regimens has greatly decreased the incidence of infection in the thoracic transplant recipient, infection remains the leading cause of death in many centers[1]–[5]. Infection is acquired exogenously through usual nosocomial and community modes of transmission, and through transfusion, or is donor-transmitted. It can also result from endogenous reactivation of latent organisms within the recipient (Table 1).
This is a preview of subscription content, log in via an institution to check access.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Preview
Unable to display preview. Download preview PDF.
References
Bourge RC, Naftel DC, Costanzo-Nordin MR et al. Pretransplantation risk factors for death after heart transplantation: a multiinstitutional study. J Heart Lung Transplant. 1993;12:549–62.
Kaye M. The Registry of the International Society for Heart and Lung Transplantation: tenth official report — 1993; J Heart Lung Transplant. 1993;12:541–8.
Chapparro C, Maurer J, Chamberlain D. Causes of death in lung transplant recipients. J Heart Lung Transplant. 1994;13:758–66.
Walley VM, Masters RG, Boone SA. et al. Analysis of deaths after heart transplantation: the University of Ottawa Heart Institute experience. J Heart Lung Transplant. 1993;12:790–801.
Bork J, Chinnock R, Ogata K et al. Infectious complications in infant heart transplantation. J Heart Lung Transplant 1993;12:S199–202
Rubin RH. Infection in the organ transplant recipient. In: Rubin R, Young L. editors. Clinical approach to infection in the compromised host, 3rd edn. New York: Plenum; 1994:629–705.
Verhoef J. Prevention of infections in the neutropenic patient. Clin Infect Dis. 1993(Suppl.2):S359–67.
Armstrong D. Protected environments are discomforting and expensive and do not offer meaningful protection. In: Brown AE, Armstrong D, editors. Infectious complications of neoplaslic diseases: Controversies in management. New York: York Medical Books. 1985:395–407.
Walsh TR, Guttendorf J, Dummer S. The value of protective isolation procedures in cardiac allograft recipients. Ann Thorac Surg. 1989;47:539–45.
Boyle EM, Burdine J, Bolman RM III, Successful treatment of Mycoplasma mediastinitis after heart-lung transplantation. J Heart Lung Transplant. 1993;12:508–12.
Counihan PJ, Yelland A, de Belder MA et al. Infective endocarditis in a heart transplant recipient. J Heart Lung Transplant. 1991;10:275–9.
Toporoff B, Rosado LJ, Appleton CP et al. Successful treatment of early infective endocarditis and mediastinitis in a heart transplant recipient. J Heart Lung Transplant. 1994;13:546–8.
Dajani AS, Bisno AL, Chung KJ et al, Prevention of bacterial endocarditis, Recommendations by the American Heart Association, J Am Med Assoc. 1990;264:2919.
Dondero TJ, Rentorff RC, Mallison GF et al. An outbreak of legionnaire’s disease associated with a contaminated air-conditioning cooling tower, N Engl J Med. 1980;302:365–70.
Klaucke DK, Vogt R, LaRue D et al. Legionnaire’s disease: the epidemiology of two outbreaks in Burlington. Vermont, 1980. Am J Epidemiol. 1984;119:382–91.
Addiss D, Davis J, LaVenture M et al. Community-acquired legionnaire’s disease associated with a cooling tower: evidence for longer-distant transport of Legionella pneumophila. Am J Epidemiol. 1989;130:557–68.
Breiman RF, Cozen W, Fields BS et al. Role of air-sampling in an investigation of an outbreak of legionnaire’s disease associated with exposure to aerosols from an evaporative condenser. J Infect Dis. 1990;161:1257–61.
Garbe P, David B, Weisfeld J et al. Nosocomial legionnaire’s disease: epidemiologic demonstration of cooling towers as a source. J Am Med Assoc. 1985;254:521–4.
Breiman RF, Fields BS, Sanden GN et al. Association of shower use with legionnaire’s disease. J Am Med Assoc. 1990;263:2924–6.
Vogt RL, Hudson PJ, Orciari L et al. Legionnaire’s disease and a whirlpool spa. (Letter). Ann Intern Med. 1987;107:596.
Arnow PM, Chou T, Weil D et al. Nosocomial Legionnaire’s disease caused by aerosolized tap water from respiratory devices. J Infect Dis. 1982;146:460–77.
Mahoney FJ, Hoge CW, Farley TA et al. Communilywide outbreak of legionnaire’s disease associated with a grocery store mist machine. J Infect Dis. 1992;165:736–9.
Redd SC, Schuster DM, Quan J et al. Legionellosis in cardiac transplant recipients: results of a nationwide survey. (Letter) J Infect Dis. 1988;158:651–2.
Edelstein PH. Legionnaire’s disease. Clin Infect Dis. 1993;16:741–9.
Yu VL. Legionnaire’s disease: new understanding of community acquired pneummonia. Hosp Pract. 1993;28:63–7.
Kilborn JA, Manz LA, O’Brien M et al. Necrotizing cellulitis caused by Legionella micdudei. Am J Med. 1992;92:104–6.
Friedland L, Snydman DR, Weingarden AS et al. Ocular and pericardial involvement in legionnaire’s disease. Am J Med. 1984;77:1105–7.
Anaissie E, Kontoyiannis DP, Kantarjan H et al. Listeriosis in patients with CLL who were treated with fludarabine and prednisone. Ann Intern Med. 1992;117:466–8.
Galpin JE, editor. Listeriosis in normal and immunocompromised hosts. Infect Dis Alert. 1992;11:101–4.
Skogberg K, Syrjanen J, Jahkola M et al. Clinical presentation and outcome of listeriosis in patients with and without immunosuppressive therapy. Clin Infect Dis. 1992;14:815–21.
Nieman RE, Lorber B. Listeriosis in adults: a changing pattern. Report of eight cases and review of the literature 1968–1978. Rev Infect Dis. 1980;2:207–27.
Heck AF, Hameroff SB, Hornick RB. Chronic Listeria monocytogenes meningitis with normotensive hydrocephalus. Case report and review. Neurology [Minneap.] 1971;21:263–70.
Buchner LH, Schneierson S. Clinical and laboratory aspects of Listeria monocytogenes infections, with a report of ten cases. Am J Med. 1968;45:904–21.
Spitzer PG, Hammer SM, Karchmer AW. Treatment of Listeria monocytogenes infection with trimethoprim-sulfamethoxazole: case report and review of the literature. Rev Infect Dis. 1986;8:427–30.
Scheer MS, Hirschman SZ, Oral and ambulatory therapy of Listeria bacteremia and meningitis with trimethoprim-sulfamethoxazole. Mt Sinai J Med. 1982;49:411–14.
Hooper DC, Pruitt AA, Rubin RH. Central nervous system infections in the chronically immunosuppressed. Medicine [Baltimore]. 1982;61:166–88.
Schuchat A, Deaver KA, Wenger JD et al. Role of foods in sporadic lisleriosis. I. Case-control study of dietary risk factors. J Am Med Assoc. 1992;267:2041–5.
Dromer C. Samer AMN, Velly JF et al. Tuberculosis in transplanted lungs. J Heart Lung Transplant. 1993;12:924–7.
Carlsen SE, Bergin CJ. Reactivation of tuberculosis in a donor lung after transplantation. AJR. 1990;154:495–7.
Higenbottam TW, Stewart S, Penketh AR et al. Transbronchial lung biopsy for the diagnosis of rejection in heart-lung transplant patients. Transplantation. 1988;46:532–9.
Trulock EP, Bolman RM, Genton R. Pulmonary disease caused by Mycobacterium chelonae in a heart-lung transplant recipient with obliterativc bronchiolilis. Am Rev Resp Dis. 1989;149:802–5.
Egan TM, Westcrman JH, Lambert CJ et al. Isolated lung transplantation for endstage lung disease: a viable therapy. Ann Thorac Surg. 1992;53:590–6.
Gentry LO, Zcluff B, Kiclhofner MA. Dermatologic manifestations of infectious diseases in cardiac transplant patients. [Review]. Infect Dis Clin N Am. 1994;8:637–54.
LcMense GP, Van Bakel AB, and Crumhley AJ III et al. Mycobacterium scrofulaceum infection presenting as lung nodules in a heart transplant recipient. Chest. 1994;106:1918–20.
Holzinger C, Laczkovics A, Imhof M et al. Tuberculosis of two cardiac allografts in one patient. Transplantation. 1994;57:1277–8.
Stephan JL, LeDiest F, Blanche S et al. Treatment of central nervous system B cell lymphoproliferative syndrome by local infusion of a B cell-specific monoclonal antibody. Transplantation. 1992;54:246–9.
Neeley SP, Denning DW. Cutaneous Mycobacterium thermoresistibile infection in a heart transplant recipient. Rev Infect Dis. 1989;11:608–11.
Tuder RM, Renya GS, Bensch K. Mycobacterial coronary artcritis in a heart transplant recipient. Human Pathol. 1986;17:1072–4.
Novick RJ, Moreno-Cabral CE, Stinson EB et al. Nontuberculous mycobactenal infections in heart transplant recipients: a seventeen year experience. J Heart Transplant. 1990;9:357–63.
Lichtenstein IH, MacGregor RR. Mycobacterial infections in renal transplant recipients: report of 5 cases and review of the literature. Rev Infec Dis. 1983;5:216–26.
Lloveras J, Peterson PK, Simmons RL et al. Mycohacterial infections in renal transplant recipients. Seven cases and review of the literature. Arch Inlern Med. 1982;142:888–92.
Riska H, Kulback B. Tuberculosis and kidney transplantation. Acta Med Scand. 1979;205:637–40.
Riska H, Gronhagen-Riska C, Ahoncn J. Tuberculosis and renal allograft transplantation. Transplant Proc. 1987;19:4096–7.
Ascher NL, Simmons RL, Marker S et al. Tuberculous joint disease in transplant patients. Am J Surg. 1978;135:853–6.
Daniels NJ, Dover JS, Schacter RK. Interaction between cyclosporin and rifampicin. Lancet. 1984;19:639.
Langhoff E, Madsen S. Rapid metabolism of cyclosporin and prednisone in kidney transplant patient receiving tubcrcutostatic treatment. Lancet. 1983;29:1031.
Modry DL, Stinson EB, Over PE et al. Acute rejection and massive cyclosporin requirements in heart transplant recipients treated with rifampin. Transplantation. 1985;39:313–14.
Offerman G, Keller F, Molzahn M. Low cyclosporin A blood levels and acute graft rejection in a renal transplant recipient during rifampicin treatment. Am J Nephrol. 1985;5:385–7.
VanBuren D, Wideman CA, Ried M et al. The antagonistic effect of rifampicin upon cyclosporin bioavailability. Transplant Proc. 1984;16:1642–5.
Comstock GW, Woolpert SH. Prophylaxis. In: Schlossberg D. editor. Tuberculosis, 2nd edn. New York: Springer-Verlag; 1988:54–9.
Thomas PA Jr. Mozes MF, and Jonasson O. Hepatic dysfunction during isoniazid chemoprophylaxis in renal allograft recipients. Arch Surg. 1979;l14:597–9.
Higgins RSD, Kusne S, and Reyes J et al. Myeobacterium tuberculosis after liver transplantation: management and guidelines for prevention. Clin Transplant. 1992;6:81–90.
Alford R. Antimycobacterial agents. In: Mandell GL. Bennett JE. Dolin R. editors. Principles and practice of infectious diseases, 4th edn. New York: Churchill Livingstone: 1995;389–400.
Arduino RC, Johnson PC, Miranda AG. Nocardiosis in renal transplant recipients undergoing immunosuppression with cyclosporin. Clin Infect Dis. 1993;16:505–12.
Wilson JP, Turner HR, Kirchner KA et al. Nocardial infections in renal transplant recipients. Medicine [Baltimore]. 1989;68:38–57.
Simpson GL, Stinson EB, Egger MJ et al. Nocardial infections in the immunocompromised host: a detailed study in a defined population. Rev Infect Dis. 1981;3:492–508.
Beaman BL, Bumside J, Edwards B et al. Nocardia infections in the United States. 1972–1974. J Infect Dis. 1976;l34:286–9.
Kong NCT, Morad Z, Suleiman AB et al. Spectrum of nocardiosis in renal patients. Ann Acad Med. Singapore. 1990;19:375–9.
Leaker B, Hellyar A, Neild GH et al. Nocardia infection in a renal transplant unit. Transplant Proc. 1989;21:2103–4.
Krick JA, Stinson EB, Remington JS. Nocardia infection in heart transplant patients. Ann Intern Med. 1975;82:18–26.
Wallace RJ Jr. Septimus EJ, Williams TJ Jr et al. Use of trimethoprim-sulfamethoxazole for treatment of infections due to Nocardia. Rev Infect Dis. 1982;4:315–25.
Wallace RJ Jr. Steele LC, and Sumter G et al. Antimicrobial susceptibility patterns of Nocardia asteroides. Antimicrob Agents Chemother. 1988;32:1776–9.
Berkey P, Moore D, Rolston K. In vitro susceptibilities of Nocardia species to newer antimicrobial agents. Antimicrob Agents Chemother. 1988;32:1078–9.
Wallace RJ Jr. Nash DR, Johnson WK et al. B-Lactam resistance in Nocardia brasiliensis is mediated by B-lactamases and reversed in the presence of clavulanic acid. J Infect Dis. 1987;156:959–66.
Filice GA, Simpson GL. Management of Nocardia infections. In: Remington JS, Swartz MN, editors. Current clinical topics in infectious diseases, Vol. 5. New York: McGraw-Hill; 1984;49–64.
Segovia J, Pulpon LA, Crespo MG et al. Rhodococcus equi: first case in a heart transplant recipient. J Heart Lung Transplant. 1994;13:332–5.
Van Etta LL, Filice GS, Ferguson RM et al. Corynebacterium equi: a review of twelve cases of human infection. Rev Infect Dis. 1983;5:1012–18.
Harvey RL, Sunstrum JC. Rhodococcus equi infection in patients with and without human immune deficiency virus infection. Rev Infect Dis. 1991;84:1217–20.
Petersen LR, Mead RH, Perlroth MG. Unusual manifestations of secondary syphilis occurring after orthotopic liver transplantation. Am J Med. 1983;75:166–70.
Gibel LJ, Sterling W, Hoy W et al. Is serological evidence of infection with syphilis a contraindication to kidney donation? Case report and review of the literature. J Urol. 1987;138:1226–7.
Paya CV. Fungal infections in solid-organ transplantation. Clin Infect Dis. 1993;16:677–88.
Dummer JS, Bahnson HT, Griffith BP et al. Infections in patients on cyclosporine and prednisone following cardiac transplantation. Transplant Proc. 1983;15(Suppl. l.2):2779–8l.
Hofflin JM, Potasman I, Baldwin JC et al. Infectious complications in heart transplant recipients receiving cyclosporin and corticosteroids. Ann Intern Med. 1987;106:209–16.
Dummer JS, Montero CG, Griffith BP et al. Infections in heart-lung transplant recipients. Transplantation. 1986;41:725–9.
Linder J. Infection as a complication of heart transplantation. J Heart Transplant. 1988;7:390–4.
Brooks RG, Hofflin JM, Jamieson SW et al. Infectious complications in heart-lung transplant recipients. Am J Med. 1985;79:412–22.
Dauber JH, Paradis IL, Dummer JS et al. Infectious complications in pulmonary allograft recipients. Clin Chest Med. 1990;11:291–308.
Gentry LO, Zeluff BJ. Diagnosis and treatment of infection in cardiac transplant patients. Surg Clin N Am. 1986;66:459–65.
Rinaldi MG. Problems in the diagnosis of invasive fungal diseases. Rev Infect Dis. 1991;13:493–5.
Dowling RD, Baladi N, Zenati M et al. Disruption of the aortic anastomosis after heart-lung transplantation. Ann Thorac Surg. 1990;49:118–20.
Thomson D, Menkis A, Pflugfelder P et al. Mycotic aortic aneurysm after heart-lung transplantation. Transplantation. 1989;47:195–7.
Anthuber M, Kemkes BM, Kreuzer E et al. Mediastinitis and mycotic aneurysm of the aorta after orthotopic heart transplantation. Tex Heart lnst J. 1991;18:186–93.
Fischman AJ, Alpert NM, Livni E et al. Pharmacokinetics of 18F-labeled fluconuzole in healthy human subjects by positron emission tomography. Antimicrob Agents Chemother. 1993;37:1270–7.
Fisher MA, Shen S-H, Haddad J et al. Comparison of in vivo activity of fluconazole with that of amphotericin B against Candida tropicalis, Candida glabrata, and Candida krusei. Antimicrob Agents Chemother. 1989;33:1443–6.
Akova M, Akalin HE, Uzun O et al. Emergence of Candida krusei infections after therapy of oropharyngeal candidiasis with fluconazole. (Letter) Eur J Clin Microbiol Infect Dis. 1991;10:598–9.
Meunicr F. Prevention of mycoses in immunocompromised patients. Rev Infecl Dis. 1987;9:408–16.
Goodman JL, Winston DJ, Greenfield RA et al. A controlled trial of fluconazole to prevent fungal infections in patients undergoing bone marrow transplantation. N Engl J Med. 1992;326:845–51.
Winston DJ, Chandrasekar PH, Lazarus HM et al. Fluconazole prophylaxis of fungal infections in patients with acute leukemia. Results of a randomized placebo-controlled, double-blind, multicenter trial. Ann Intern Med. 1993;118:495–503.
Wingard JR, Merz WG, Rinaldi MG et al. Increase in Candida krusei infection among patients with bone marrow transplantation and neutropenia treated prophylactically with fluconazole. N Engl J Med. 1991;325:1274–7.
Hilton E, Isenberg HD, Alperstein P et al. Ingestion of yogurt containing Lactobacillus acidophilus as prophylaxis for Candidal vaginitis. Ann Intern Med. 1992;116:353–7.
Weiland D, Ferguson RM, Peterson PK, et al. Aspergillosis in 25 renal transplant patients. Epidemiology, clinical presentation, diagnosis, and management. Ann Surg. 1983;198:622–9.
Gurwith MJ, Stinson EB, Remington JS. Aspergillus infection complicating cardiac transplantation. Arch Intern Med. 1971;128:541–5.
Montero CG, Martinez AJ. Neuropathology of heart transplantation: 23 cases. Neurology. 1986;36:1149–54.
Denning DW, Stevens DA. Antifungal and surgical treatment of invasive aspergillosis: review of 2,121 published cases. Rev Infect Dis. 1990;12:1147–1201.
Shamberger RC, Weinstein HJ, Grier HE et al. The surgical management of fungal pulmonary infections in children with acute myelogenous leukemia. J Pediatr Surg. 1985;20:840–4.
Mayer J-M, Nimer L, Carroll K. Isolated aspergillar infection in cardiac transplant recipients: case report and review. Clin Infect Dis. 1992;15:698–700.
Bodey GP, Varvitarian S. Aspergillosis. Eur J Clin Microbiol Infect Dis. 1989;148:230–8.
Meunier F. Fungal infections in the compromised host. In: Rubin RH, Young LS, editors. Clinical approach to infection in the compromised host, 2nd edn. New York: Plenum; 1988;193–216.
Arnow PM, Andersen RL, Mainous PD et al. Pulmonary aspergillosis during hospital renovation. Am Rev Resp Dis. 1978;118:49–53.
Kyriakides GK, Zinneman HH, Hall WH et al. Immunologic monitoring and aspergillosis in renal transplant patients. Am J Surg. 1976;131:246–52.
Lentino JR, Rosenkranz MA, Michaels JA et al. Nosocomial aspergillosis: a retrospective review of airborne disease secondary to road construction and contaminated air conditioners. Am J Epidemiol. 1982;116:430–7.
Meyers JD, Atkinson K. Infection in bone marrow transplantation. Clin Hematol. 1983;12:791–811.
Milliken ST, Powles RL. Antifungal prophylaxis in bone marrow transplantation. Rev Infect Dis. 1990;l2(Suppl.3):S374–9.
Winston DJ, Ho WG, Gale RP et al. Prophylaxis of infection in bone marrow transplants. Eur J Cancer Clin Oncol. 1988;24(Suppl. 1):S15–23.
Bennett JE, Dismukes WE, Duma RJ et al. A comparison of amphotericin B alone and combined with flucytosine in the treatment of cryptococcal meningitis. N Engl J Med. 1979;301,126–31.
Conti DJ, Tolkoff-Rubin NE, Baker GP Jr et al. Successful treatment of invasive fungal infection with fluconazole in organ transplant recipients. Transplantation. 1989;48:692–5.
Stevens D. Coccidioides immitis. In: Mandell GL, Bennett JE, Dolin R, editors. Principles and practice of infectious diseases. 4th edn. New York: Churchill Livingstone; 1995;2365–75.
Brewer JH, Parrott CL, Rimland D. Disseminated coccidioidomycosis in a heart transplant patient. Sabouraudia. 1982;20:261–5.
Vartivarian SE, Coudron PE, Markowitz SM. Disseminated coccidioidomycosis. Unusual manifestations in a cardiac transplantation patient. Am J Med. 1987;83:949–52.
Hall KA, Sethi GK, Rosado LJ et al. Coccidioidomycosis and heart transplantation. J Heart Lung Transplant. 1993;12:525–6.
Catanzaro A, Galgiani JN. Fluconazole in the treatment of chronic pulmonary and nonmeningeal disseminated coccidioidomycosis. Am J Med. 1995;98:249–56.
Hyde L. Coccidioidal pulmonary cavitation. Dis Chest. 1968;54(Suppl. 1):273.
Goodwin RA Jr. Shapiro JL, Thurman GH et al. Disseminated histoplasmusis: clinical and pathological correlates. Medicine. 1980;59:1–32.
Wheat LJ, Connolly-Stringfield PA, Baker RL et al Disseminated histoplasmosis in the acquired immunodeficiency syndrome: clinical findings, diagnosis and treatment, and review of the literature. Medicine [Baltimorc]. 1990;69:361–74.
Bullock WE. Histoplasma capsulatum. In: Mandell GL, Bennett JE, Dolin R. editors. Principles and practice of infectious diseases, 4th edn. New York: Churchill Livingstone; 1995;2340–53.
Wheat LJ. Systemic fungal infections: diagnosis and treatment. I. Hisloplasmosis. Infect Dis Clin N Am. 1988;2:841–59.
Wheat LJ, Kohler RB, Tewari RP. Diagnosis of disseminated histoplasmosis by detection of Histoplasma capsulatum antigen in serum and urine specimens. N Engl J Med. 1986;314:83–9.
Davies SF. Serodiagnosis of histoplasmosis. In: Sarosi GA. editor. Seminars in respiratory infections. Orlando, FL: Grune & Stratton, 1986;1:9–15.
Goodwin RA, Loyd JE, des Prez RM. Histoplasmosis in normal hosts. Medicine. 1981;60:231–66.
Wheat LJ, Hafner R, Wulfsohn M et al. Prevention of relapse of histoplasmosis with itraconazole in patients with the acquired immunodeficiency syndrome. Ann Intern Med 1993;118:610–16.
Dismukes WE, Bradsher RW Jr. Cloud GC et al. Itraconazole therapy for blastomycosis and hisloplasmosis. Am J Med. 1992;93:489–97.
Negroni R, Robles AM, Arechavala A et al. Keloconazole in the treatment of paracoccidioidomycosis and histoplasmosis. Rev Infect Dis. 1980;2:643–9.
Wheat LJ, Hafner RE, Ritchie M et al. Itraconazole is effective treatment for histoplasmosis in AIDS: prospective multicenter non-comparative trials. In: Proceedings of the 32nd ICAAC. Anaheim, CA; 1992; 312.
Deepe GS Jr. Bullock WE. Histoplasmosis: a granulomatous inflammatory response. In: Gallin JI, Goldstein IM, Snyderman R, editors. Inflammation: basic principles and clinical correlates, 2nd edn. New York: Raven Press: 1992:943.
Gomez FJ, Gomez AM, Deepe GS. An 80-kDalton antigen from Histoplasma capsulatum that has homology to heat-shock protein 70 induces cell-mediated immune responses and protection in mice. Infect Immun. 1992;60:2565–71.
Serody JS Mill MR, Detterbeck FC et al. Blastomycosis in transplant recipients: report of a case and review. Clin Infect Dis. 1993;16:54–8.
Butka BJ, Bennett SR, Johnson AC. Disseminated inoculation blastomycosis in a renal transplant recipient. Am Rev Resp Dis. 1984;130:1180–3.
Greene NB, Baughman RP, Kim CK et al. Failure of ketoconazole in a renal transplant patient with pulmonary blastomycosis. Chest. 1985;88:640–l.
Hii JH, Legault L, DeVeber G et al. Successful treatment of systemic blastomycosis with high-dose ketoconazole in a renal transplant recipient. Am J Kidney Dis. 1990;14:595–7.
Pechan WB, Novick AC, Lalli A et al. Pulmonary nodules in a renal transplant recipient. J Urol. 1980;124:11–14.
Winston DJ, Gale RP, Meyer DV et al. Infectious complications of human bone marrow transplantation. Medicine [Baltimore]. 1979;56:1–31.
Restrepo A. Paracoccidioides brasiliensis. In: Mandell GL, Bennett JE, Dolin R, editors. Principles and practice of infectious diseases, 4th edn. New York: Churchill Livingstone; 1995;2386–9.
Sugar AM, Restrepo A, Stevens DA. Paracoccidioidomycosis in the immunosuppressed host. Report of a case and review of the literature. Am Rev Resp Dis. 1984;129:349–52.
Bennett JE. Miscellaneous fungi. In: Mandell GL, Bennett JE, Dolin R, editors. Principles and practice of infectious diseases, 4th edn. New York: Churchill Livingstone; 1995;2389–93.
Alsip SG, Cobbs CG. Pseudoallescheria boydii infection of the central nervous system in a cardiac transplant recipient. South Med J. 1986;79:383–4.
Winston DJ, Jordan MC, Rhoses J. Allescheria boydii infections in the immuno-suppressed host. Am J Med. 1977;63:830.
Travis LB, Roberts GD, Wilson WR. Clinical significance of Pseudoallescheria boydii: a review of 10 years’ experience. Mayo Clin Proc 1985;60:531–7.
Kolbeck PC, Makhoul RG. Bollinger RR et al. Widely disseminated Cunninghamella muconmycosis in an adult renal transplant patient: case report and review of the literature. Am J Clin Pathol. 1975;64:544–8.
Myskowski PL, Brown AE, Dinsmore R et al. Mucormycosis following bone marrow transplantation. J Am Acad Dermatol. 1983;9:111–15.
Morduchowicz G, Schmueli D, Shapira Z et al. Rhinocerebral mucormycosis in renal transplant recipients: report of three cases and review of the literature. Rev Infect Dis. 1986;8:441–6.
Henriquez M, Levy R, Raja RM et al. Mucormycosis in a renal transplant recipient with a successful outcome. J Am Med Assoc. 1979;242:1397–9.
Bribetz AR, Chuang MT, Burrows L et al. Rhizopus lung abscess in a renal transplant patient successfully treated by lobectomy. Chest. 1980;77:102–4.
Sugar A. Agents of mucormycosis and related species. In: Mandell GL, Bennett JE, Dolin R, editors. Principles and practice of infectious diseases, 4th edn. New York: Churchill Livingstone; 1995;2311–21.
Fader RC, McGinnis MR. Infections caused by dematiaceous fungi: chromoblastomycosis and phaeohyphomycosis. Infect Dis Clin N Am. 1988;2:925–38.
Sudduth E, Crumbley AJ III, Farrar WE. Phaeohyphomycosis due to Exophiala species: clinical spectrum of disease in humans. Clin Infect Dis. 1992;15:639–44.
Haupt HM, Merz WG, Beschorncr WE et al. Colonization and infection with Trichosporon species in the immunosuppressed host. J Infect Dis. 1983;147:199.
Hoy H, Hsu KC, Rolston H et al. Trichosporon beigelii infection: a review. Rev Infect Dis. 1986;8:959–67.
Kim JH, Perfect JR. Infection and cyclosporin. Rev Infect Dis. 1989;11:677–90.
Kennedy MS, Deeg HJ, Siegel M et al. Acute renal toxicity with combined use of amphotericin B and cyclosporin after marrow transplantation. Transplantation. 1983;35:211–15.
Heidemann HT, Gerkens J, Spickard WA et al. Amphotericin B nephrotoxicity in humans decreased by salt repletion. Am J Med. 1983;75:476–81.
Lopez-Berestein G. Liposomal amphotericin B in the treatment of fungal infections. Ann Intern Med. 1986;12:233–7.
Lopez-Berestein G, Bodey GP, Frankel LS et al. Treatment of hepatosplenic candidiasis with liposomal-amphotericin B. J Clin Oncol. 1987;5:310–17.
Weber RS, Lopez-Berestein G. Treatment of invasive aspergillosis sinusitis with liposomal-amphotericin B. Laryngoscope. 1987;97:937–41.
Lopez-Berestein G, Bodey GP, Fainstein V et al. Treatment of systemic fungal infections with liposomal-ampholericin B. Arch Intern Med. 1989;149:2533–6.
Patterson TF, Andriole VT. The role of liposomal amphotericin B in the treatment of systemic fungal infections. Eur J Cancer Clin Oncol. 1989;25(Suppl.2):S63–8.
Sculier JP, Bron D, Coune A et al. Successful treatment with liposomal amphotericin B in two patients with persisting fungemia. Eur J Clin Microbiol Infect Dis. 1989;8:903–7.
Ringden O, Meunier F, Tollemar J et al. Efticacy of amphotericin B encapsulated in liposomes (AmBisome) in the treatment of invasive fungal infections in immunocompromised patients. J Antimicrob Chemother. 1991;28(Suppl.B):73–82.
Meunier F, Prentice HG, Ringden O. Liposomal amphotericin B (AmBisome): safety data from a phase II/III clinical trial. J Amtimicrob Chemother. 1991;28(Suppl.B):83–91.
Chopra R, Blair S, Strang J et al. Liposomal amphotericin B (AmBisome) in the treatment of fungal infections in neutropenic patients. J Antimicrob Chemother. 1991;28(Suppl.B):93–104.
Katz NM, Pierce PF, Anzeck RA et al. Liposomal amphotericin B for treatment of pulmonary aspergillosis in a heart transplant patient. J Heart Transplant. 1990;9:14–17.
Sugar AM, Saunders C, Idelson BA et al. Interaction of fluconazole and cyclosporin. Ann Intern Med. 1989;110:844.
Byrne WR, Wajszczuk CP. Cryptococcal meningitis in the acquired immunodeficiency syndrome (AIDS): successful treatment with fluconazole after failure of amphotericin B. Ann Intern Med. 1988;108:384–5.
Robinson PA, Knirsch AK, Joseph JA. Fluconazole for life-threatening fungal infections in patients who cannot be treated with conventional antifungal agents. Rev Infect Dis. 1990;12(Suppl.3):S349–63.
Larsen RA, Leal MAE, Chan LS. Fluconazole compared with amphotericin B plus flucytosine for cryptococcal meningitis in AIDS: a randomized trial. Ann Intern Med. 1990;113:183–7.
Saag MS, Powderly WG, Cloud GA et al. Comparison of amphotericin B with fluconazole in the treatment of acute AIDS-associated cryptococcal meningitis. N Engl J Med. 1992;326:83–9.
Van Cutsem J, Van Gerven F, Janssen PAJ. Oral and parenteral therapy with saperconazole (R66905) of invasive aspergillosis in normal and immunocompromised animals. Antimicrob Agents Chemother. 1989;33:2063–8.
Denning DW, Hanson LH, Stevens DA. In vitro activity of saperconazole (R66905) compared with amphotericin B and itraconazole against Aspergillus species. Eur J Clin Microbiol Infect Dis. 1990;9:693–7.
Ho M. Cytomegalovirus: biology and infection. In: Greenough WB. Merigan TC. editors. Current topics in infectious disease. New York: Plenum; 1982:20.
Pass RF, August AM, Dworsky M et al. Cytomegalovirus infection in a day care center. N Engl J Med. 1982;307:477–9.
Preiksaitis JK, Rosno S, Grumet C et al. Infections due to herpesviruses in cardiac transplant recipients: role of the donor heart and immunosuppressive therapy. J Infect Dis. 1983;147:974–81.
Rubin RH. Impact of cytomegalovirus infection on organ transplant recipients. Rev Infect Dis. 1990;l2(Suppl.7):S754–66.
Betts RF, Freeman RB, Douglas RH Jr et al. Transmission of cytomegalovirus infection with renal allograft. Kidney Int. 1975;8:385–92.
Singh N, Dummer JS, Kusne S et al. Infections with cytomegalovirus and other herpesviruses in 121 liver transplant recipients: transmission by donated organ and the effect of OKT3 antibodies. J Infect Dis. 1988;158:124–31.
Dummer JS, Hardy A, Poorsattar A et al. Early infections in kidney, heart, and liver transplant recipients on cyclosporin. Transplantation. 1983;36:259–67.
Cooper DK, Lanza RP, Oliver S et al. Infectious complications after heart transplantations. Thorax. 1983;38:822–8.
Burke CM, Glanville A, Macoviac M et al. The spectrum of CMV infection following human heart-lung transplantation. Chest. 1984;86:824–9.
Ho M. Cytomegalovirus: biology and infection, 2nd edn. New York: Plenum: 1991.
Chou S. Acquisition of donor strains of cytomegalovirus by renal-transplant recipients. N Engl J Med. 1986;314:1418–23.
Chou S. Cytomegalovirus infection and reinfection transmitted by heart transplantation. J Infect Dis. 1987;155:1054–6.
Grundy JE, Lui S, Super M et al. Symptomatic cytomegalovirus infection in seropositive patients: reinfection with donor virus rather than reactivation of recipient virus. Lancet. 1988;2:132–5.
Mach M, Stamminger TH, Jahn G. Human cytomegalovirus: recent aspects from molecular biology. J Gen Virol 1989;70:3117–46.
Fenner F, McAuslan BR, Mims CA et al., editors. The biology of animal viruses, 2nd edn. New York: Academic Press; 1974;452–8.
Stevens JG. Latent characteristics of selected herpesviruses. Adv Cancer Res. 1978;26:227–56.
Jordan MC. Latent infection and the elusive cytomegalovirus. Rev Infect Dis. 1983;5:205–16.
Ho M. Cytomegalovirus. In: Mandell GL, Bennett JE, Dolin R, editors. Principles and practice of infectious diseases, 4th edn. New York: Churchill Livingstone; 1995;1351–64.
Padgett BL, Walker DL, zuRhein GM et al. Cultivation of a papova-likc virus from human brain with progressive multifocal leukoencephalopathy. Lancet. 197l;l:1257–60.
Quinnan GV Jr. Kirmani N, Rook AH et al. Cytotoxic T cells in cylomegalovirus infection: HLA-restricted T-lymphocyte and non-T-lymphocyte cytotoxic responses correlate with recovery from cytomegalovirus infection in bone-marrow transplant recipients. N Engl J Med. 1982;307:7–13.
Rook AH, Quinnan GV Jr. and Frederick WJ et al. Importance of cytotoxic lymphocytes during cytomegalovirus infection in renal transplant recipients. Am J Med. 1984;76:385–92.
Andreone PA, Olivari MT, Elick B et al. Reduction of infectious complications following heart transplantation with triple drug immunotherapy. J Heart Transplant. 1986;5:13–19.
Calhoon JH, Nichols L, Davis R et al. Single lung transplantation: factors in postoperative cytomegalovirus infection. J Thorac Cardiovasc Surg. 1992;l:21–6.
Rubin RH, Tolkoff-Rubin NE. Antimicrobial strategies in the care of organ transplant recipients. Antimicrob Agents Chemother. 1993,37:619–24.
Rubin RH. Infectious disease complications of renal transplantation. Kidney Int. 1993;44:221–36.
Cheeseman SH, Rubin RH, Stewart JA et al. Controlled clinical trial of prophylactic human leukocyte interferon in renal transplantation. Effect on cytomegalovirus and herpes simplex virus infection. N Engl J Med. 1981;300:1345–49.
Pass RF, Reynolds DW, Whelchel JD et al. Impaired lymphocyte transformation response to cytomegalovirus and phytohemagglutinin in recipients of renal transplants: association with antithymocyte globulin. J Infect Dis. 1981;143:259–65.
Marker SC, Howard RJ, Simmons RL et al. Cytomegalovirus infection: a quantitative prospective study of 320 consecutive renal transplants. Surgery. 1981;89:660–71.
Rubin RH, Cosimi AB, Hirsch MS et al. Effects of antithymocyle globulin on cytomcgalovirus infection in renal transplant recipients. Transplantation. 1981;31:143–5.
Hibberd PL, Tolkhoff-Rubin NE, Cosimi AB et al. Symptomatic cytomegalovirus disease in the cytomegalovirus positive recipient treated with OKT3. Transplantation. 1992;53:68–72.
Gonwa TA, Capehart JE, Pilcher JW et al. Cytomegalovirus myocarditis as a cause of cardiac dysfunction in a heart transplant recipient. Transplanlation. 1989;47:197–9.
Dummer JS, White L; Ho M et al. Morbidity of cytomegalovirus infection in heart or heart-lung transplants who received cyclosporin. J Infect Dis. 1985;152:1182–92.
Prieto M, Lake K, Pritzker M et al. OKT3 induction and steroid-free maintenance immunosuppression for treatment of high-risk heart transplant recipients. J Heart Lung Transplant. 1991;10:901–11.
Costanzo-Nordin MR, Swinnen LJ, Fisher SG et al. Cytomcgalovirus infections in heart transplant recipients: relationship to immunosuppression. J Heart Lung Transplant. 1992;11:837–46.
Lake KD, Anderson DJ, Milfred S et al. The incidence of cylomegalovirus disease in not increased after OKT3 induction therapy. (Letter) J Heart Lung Transplant. 1993;12:537–8.
Kirklin JK, Naftel DC, Levine TB et al. Cytomegalovirus after heart transplantation. Risk factors for infection and death: a multiinstitutiunal study. J Heart Lung Transplant. 1994;13:394–104.
Peterson PK, Balfour HH Jr. Marker SC et al. Cytomegalovirus disease in renal transplant allograft recipients: a prospective study of the clinical features, risk factors and impact of renal transplantation. Medicine [Baltimore]. 1980;59:283–300.
Maurer JR, Tullios DE, Scavuzzo M et al. Cytomegalovirus infection in isolated lung transplantations. J Heart Lung Transplant. 1991;10:647–9.
Duncan AJ, Dummer JS, Paradis IL et al. Cytomegalovirus infection and survival in lung transplant recipients. J Heart Lung Transplant. 1991;10:638–16.
Gould FK, Freeman MB, Taylor CE et al. Prophylaxis and management of cylomegalovirus pneumonitis after lung transplantation: a review of experience in one center. J Heart Lung Transplant. 1993;12:695–9.
Mayoral JL, Loefller CM, Fasola CG et al. Diagnosis and treatment of cytomegalovirus disease in transplant patients bused on gastrointestinal tract manifestations. Arch Surg. 1991;126:202–6.
Fiala M, Chatterjee SN, Carson S et al. Cytomegalovirus retinitis secondary to chronic viremia in phagocytic leukocytes. Am J Ophthalmol. 1977;84:1977.
Murray HW, Knox DL, Green WR et al. Cytomegalovirus retinitis in adults: a manifestation of disseminated viral infection. Am J Med. 1977;63:574–84.
Goodgame RW. Gastrointestinal cytomegalovirus disease. Ann Intern Med. 1993;119:924–35.
Van Thiel DH, Gavaler JS, Schode RR et al. Cytomegalovirus infection and gastric emptying. Transplantation. 1992;54:70–3.
Sakr M, Hassanein T, Gavaler J et al. Cytomegalovirus infection of the upper gastrointestinal tract following liver transplantation — incidence, location, and severity in cyclosporin-and FK506-treated patients. Transplantation. 1992;53:786–91.
Arabia F, Rosado LJ, Huston CL et al. Incidence and recurrence of gastrointestinal cytomegalovirus infection in heart transplantation. Ann Thorac Surg. 1993;55:8–11.
Sutherland DER, Chan FY, Foucar E et al. The bleeding cecal ulcer in transplant patients. Surgery. 1980;86:386–98.
Patel NP, Corry RJ. Cytomegalovirus as a cause of cecal ulcer with massive hemorrhage in a renal transplant recipient. Am Surg. 1980;46:260–2.
Kaplan CS, Petersen EA, Icenogle TB et al. Gastrointestinal cytomegalovirus infection in heart and heart-lung transplant recipients. Arch Intern Med. 1989;149:2095–100.
Schulman LL, Reison DS, Austin JHM et al. Cytomegalovirus pneumonitis after cardiac transplantation. Arch Intern Med. 1991;151:1118–24.
Okrent DG, Abraham E. Winston DJ. Cardiorespiratory patterns in viral septicemia. Am J Med. 1987;83:681–6.
Sayage L, Gunby R, Gonwa T et al. Cytomcgalovirus endometritis after liver transplantation. Transplantation. 1990;49:815–18.
Dorfman LJ. Cytomegalovirus encephalitis in adults. Neurology. 1973;23:136–43.
Spitzer PG, Tarsy D, Eliopulos GM. Acute transverse myelitis during disseminated cytomegalovirus infection in a renal transplant recipient. Transplantation. 1987;44:151–3.
Bale JF Jr. Human cytomegalovirus infection and disorders of the nervous system. Arch Neurol. 1984;41:310–20.
Minars N, Silverman JF, Escobar MR et al. Fatal cytomegalovirus inclusion disease: associated skin manifestations in a renal transplant patient. Arch Dermatol. 1977;113:1569–71.
Schutze WP. Kirklin JK, Cummings OW et al. Cytomegalovirus hemorrhoiditis in cardiac allograft recipients. Transplantation. 1991;51:918–20.
Paya CV, Hermans PE, Wiesner RH et al. Cytomegalovirus hepatitis in liver transplantation: prospective analysis of 93 consecutive orthotopic liver transplantations. J Infect Dis. 1989;160:752–8.
Shorr RI, Longo WL, Oberley TD et al. Cytomegalovirus-associated tubulointerstitial nephritis in an allogeneic bone marrow transplant recipient. Ann Intern Med. 1987;107:351–2.
McCarthy JM, McLoughlin MG, Shackleton CR et al. Cytomegalovirus epididymitis following renal transplantation. J Urol. 1991;146:417–19.
Min KW, Wickemeyer WJ, Chandran P et al. Fatal cytomegalovirus infection and coronary arterial thromboses after heart transplantation: a case report. J Heart Transplant. 1987;6:2100–5.
Chou S. Newer methods for diagnosis of cylomegalovirus infection. Rev Infect Dis. 1990;l2(Suppl.7):S727–36.
Farrell HE, Shellam GR. Protection against murine cytomegalovirus infection by passive transfer of neutralizing and non-neutralizing monoclonal antibodies. J Gen Virol. 1991;72:149–56.
Gleaves CA, Smith TF, Shuster EA et al. Comparison of standard tube and shell vial culture techniques for (he detection of cytomegalovirus in clinical specimens J Clin Microbiol. 1985;21:217–21.
Erice A, Holm MA, Gill PC et al. Cytomegalovirus (CMV) anligenemia assay is more sensitive than the shell vial cultures for rapid detection of CMV in polymorphonuclcar blood leukocytes. J Clin Microbiol. 1992;30.2822–5.
The TH, van der Ploeg M, and van der Berg AP et al. Direct detection of cytomegalovirus in peripheral blood leukocytes — a review of the antigenemia assay and polymerase chain reaction. Transplantation. 1992;54:193–8.
van der Bij W, Forensma R, van Son WJ et al. Rapid immunodiagnosis of active cytomegalovirus infection by monoclonal staining of blood leucocytes. J Med Virol. 1988;25:179–88.
van der Bij W, van Dyck RB, and van Son WJ et al. Antigen lest for early diagnosis of active cytomegalovirus infection in heart transplant recipients. J Heart Transplant. 1988;7:106–10.
van den Berg AP, van der Bij W, and van Son WJ et al. Cytomegalovirus antigenemia as a useful marker of symptomatic cytomegalovirus infection after renal — transplantation — a report of 130 consecutive patients. Transplantation. 1989;48:991–5.
van den Berg AP, Klompmaker IJ, Haagsma EB et al. Antigcnemia in the diagnosis and monitoring of active cytomegalovirus infection after liver transplantation. J Infect Dis. 1991;164:265–70.
van den Berg AP, Tegzess AM, and Scholten-Sampson A et al. Monitoring antigenemia is useful in guiding treatment of severe cytomegalovirus disease after organ transplantation. Transplant Int. 1992;5:101–7.
Gerna G, Revello MG, Percivalle F. et al. Quantification of human cytomegalovirus viremia by using monoclonal antibodies to different proteins. J Clin Microbiol. 1990;28:2681–8.
Miller H, Rossier E, Milk R et al. Prospective study of cytomegalovirus antigenemia in allograft recipients. J Clin Microbiol. 1991;29:1054–5.
Gerna G, Zipeto D, Parea M et al. Monitoring of human cytomegalovirus infection and ganciclovir treatment in heart transplant recipients by determination of viremia. antigenemia. and DNAemia. J Infect Dis. 1991;164:488–98.
Boland GJ, Verves C, Hene RJ et al. Early detection of primary cytomegalovirus infection after heart and kidney transplantation and the influence of hyperimmune globulin prophylaxis. Transplant Int. 1993;6:34–8.
Kosleinen PK, Nieminen MS, Mattila SP et al. The correlation between symptomatic CMV infection and CMV antigenemia in heart allograft recipients Transplantation. 1993;55:547–55.
Crawford SW, Bowden RA, Hackman RC et al. Rapid detection of cytomegalovirus infection by bronchoalveolar lavage and centrifugation culture. Ann Intern Med. 1984;108:180–5.
Stockel E, Popow-Kraupp T, Heinz FX et al. Potential of in situ hybridization for early diagnosis of productive cytomegalovirus infection. J Clin Microbiol. 1988;26:2536–40.
Saiki RK, Scharf S, Faloona F et al. Enzymatic amplification of B-globulin genomic sequences and restriction site analysis for diagnosis of sickle cell anemia. Science. 1985;230:1350–4.
Demmler GJ, Buffone GJ, Schimbor CM et al. Detection of cylomegalovirus in urine from newborns by using polymerase chain reaction DNA amplification. J Infect Dis. 1988;158:1177–84.
Shibata D, Martin WJ, Applcman MD et al. Detection of cytomegalovirus DNA in peripheral blood of patients infected with human immunodeficiency virus. J Infect Dis. 1988;158:1185–92.
Bitsch A, Kirchner H, Dupke R et al. Cytomegalovirus transcripts in peripheral blood leukocytes of actively infected transplant patients detected by reverse transcription-polymerase chain reaction. J Infect Dis. 1993;167:740–3.
Duncan SR, Cook DJ. Survival of ganciclovir-treated heart transplant recipients with cytomegalovirus pneumonitis. Transplantation. 1991;52:910–13.
Cooper DKC, Novitzky D. Schlegel V et al. Successful management of symptomatic cytomegalovirus disease with ganciclovir after heart transplantation. J Heart Lung Transplant. 1991;10:656–63.
Dunn DL, Mayoral JL, Gillingham KJ et al. Treatment of invasive cytomegalovirus disease in solid organ transplant patients with ganciclovir. Transplantation. 1991;51:98–106.
Paya CV, Hermans PE, Smith TF et al. Efficacy of ganciclovir in liver and kidney transplant recipients with severe CMV infection. Transplantation. 1988;46:229–34.
Harbison MA, De Giroliani PC, Jenkins RL et al. Ganciclovir therapy of severe cytomegalovirus infection in solid organ transplant recipients. Transplantation. 1988;46:82–8.
Erice A, Jordan MC, Chace BA et al. Ganciclovir treatment of cytomegalovirus disease in transplant recipients and other immunocompromised hosts. J Am Med Assoc. 1987;257:3082–7.
Watson FS, O’Connell JB, Amber IJ et al. Treatment of cytomegalovirus pneumonia in heart transplant recipients with 9(1.3-dihydroxy-2-propoxymethyl)-guanine (DHPG). J Heart Transplant. 1988;7:102–5.
Keay S, Petersen EA, Icenogle TB et al. Ganciclovir treatment of serious cytomegalovirus infection in heart and heart-lung transplant recipients. Rev Infect Dis. 1988;10(Suppl.3):S563–72.
Icenogle TB, Petersen EA, Ray G et al. DHPG effectively treats CMV infection in heart and heart-lung transplant patients: a preliminary report. J Heart Transplant. 1987;6:199–203.
Reed EC, Bowden RA. Dandliker PS et al. Efficacy of cytomegalovirus immunoglobulin in marrow transplant recipients with cytomegalovirus pneumonia. J Infect Dis. 1987;156:641–5.
Reed EC, Bowden RA, Dandliker PS et al. Treatment of cytomegalovirus pneumonia with ganciclovir and intravenous cytomegalovirus immunoglobulin in patients with bone marrow transplants. Ann Intern Med. 1988;109:783–8.
Emanuel D, Cunningham I, Jules-Elysee K et al. Cytomegalovirus pneumonia after bone marrow transplantation successfully treated with combination of ganciclovir and high-dose intravenous immune globulin. Ann Intern Med. 1988;109:777–82.
Rubin RH, Wilson EJ, Barrett LV et al. The protective effects of hyperimmune anti-murine cytomegalovirus antiserum against lethal viral challenge: the case for passive-active immunization. Clin Immunol Immunopathol. 1986;39:151–8.
Erice A, Chou S, Biron KK et al. Progressive disease due to ganciclovir resistant cytomegalovirus in immunocompromised patients. N Engl J Med. 1989;320:289.
Locke TJ, Odom NS, Tapson JS et al. Successful treatment with trisodium phosphonoformate for primary cytomegalovirus infection after heart transplantation. J Heart Transplant. 1987;6:120–2.
Klintmalm G, Lonnqvist B, Oberg B et al. Intravenous foscamet for the treatment of severe cytomegalovirus infection in allograft recipients. Scand J Infect Dis. 1985;17:157–63.
Ludwin D, White N, Tsai S et al. Results of prospective matching for cytomegalovirus status in renal transplant recipients. Transplant Proc. 1987;19:3433–4.
Ackermann JR, LeFor WM, Weinstein S, et al. Four-year experience with exclusive use of cytomegalovirus antibody (CMV-Ab)-negative donors for CMV-Ab-negative kidney recipients. Transplant. Proc. 1988;1(Suppl. 1):469–71.
Wreghitt T. Cytomegalovirus in heart and heart-lung transplant recipients. J Antimicrob Chemother. 1989;23(Suppl.E):49–60.
Bowden RA, Sayers M, Flournoy N et al. Cytomegalovirus immunoglobulin and seronegative blood products to prevent primary cytomegalovirus infection after bone marrow transplant. N Engl J Med. 1986;314:1006–10.
Adler SP, Chandrika T, Lawrence T et al. Cytomegalovirus infections in neonates acquired by blood transfusions. Pediatr Infect Dis. 1983;2:114–18.
Diosi P, Moldovan E, Tomescu N. Latent cytomegalovirus infection in blood donors. Br Med J. 1969;4:660–2.
Tegtmeier GE. Transfusion-transmitted cytomegalovirus infections: significance and control. Vox Sang. 1986;51(Suppl.):22–30.
Armstrong JA, Tarr GC, Youngblood LA et al. Cytomegalovirus infection in children undergoing open-heart surgery. Yale J Biol Med. 1975;49:83–91.
Preiksaitis JK, Brown L, Mackenzie M. The risk of cytomegalovirus infection in seronegative transfusion recipients not receiving exogenous immunosuppression. J Infect Dis. 1988;157:523–9.
DeWitte T, Schattenberg A, van Dijk BA et al. Prevention of primary cytomegalovirus infection after allogeneic bone marrow transplantation by using leukocyte-poor random blood products from cytomegalovirus-unscreened blood bank donors. Transplantation. 1990;50:964–8.
Sayers MH, Anderson KC, Goodnough LT et al. Reducing the risk for transfusion-transmitted cylomegalovirus infection. Ann Intern Med. 1992;116:55–62.
Lamberson HV Jr. McMillan JA, Weiner LB et al. Prevention of transfusion-associated cytomegalovirus (CMV) infection in neonates by screening blood donors for IgM to CMV. J Infect Dis. 1988;157:820–2.
Meyers JD, Leszczynski J, Zaia JA et al. Prevention of cytomegalovirus infection by cytomegalovirus immune globulin after bone marrow transplantation. Ann Intern Med. 1983;98:442–6.
Winston DJ, Pollard RB, Ho WG et al. Cytomegalovirus immune plasma in bone marrow transplant recipients. Ann Intern Med. 1982;97:11–18.
Winston DJ, Ho WG, Cheng-Hsien L et al. Intravenous immune globulin for prevention of cytomegalovirus infection and interstitial pneumonia after bone marrow transplantation. Ann Intern Med. 1987;106:12–18.
Snydman DR, Werner BG, Heinze-Lacey B et al. Use of cytomegalovirus immune globulin to prevent cytomegalovirus disease in renal transplant recipients. N Engl J Med. 1987;3127:1049–54.
Snydman DR, Werner BG, Tilney NL et al. A further analysis of primary cytomegalovirus disease prevention in renal transplant recipients with a cytomegalovirus immune globulin: interim comparison of a randomized and an open-label trial. Transplant Proc. 1988;20:24–30.
Snydman DR. Review of the efficacy of cytomegalovirus immune globulin in the prophylaxis of CMV disease in renal transplant recipients. Transplant Proc. 1993;25(Suppl.4):25–6.
Melselaar HJ, Balk AHMM, and Mochtar B et al. Cytomegalovirus seronegative heart transplant recipients: prophylactic use of anti-CMV immunoglobulin. Chest. 1990;97:396–9.
Snydman DR, Werner BG, Dougherty NN et al. Cytomegalovirus immune globulin prophylaxis in liver transplantation. Ann Intern Med. 1993;19:984–91.
Saliba F, Arulnaden JL, Gugenheim J et al. CMV hyperimmune globulin prophylaxis after liver transplantation: a prospective randomized controlled study. Transplant Proc. 1989;21:2260–2.
Roy DM, Grundy JE, Evaluation of neutralizing antibody titers against human cytomegalovirus in intravenous gamma globulin preparations. Transplantation. 1992;54:1109–10.
Gibert R, Habib R, Allard JP et al. Prevalence of CMV ELISA antibody: titer and neutralizing activity in intramuscular immune globulin of placental origin. Transplant Proc. 1988;20:24–30.
Emanuel D. Issues concerning the use of intravenous immunoglobulin for the immunoprophylaxis of cytomegalovirus infections in allogeneic bone marrow transplant recipients. Monogr Allergy (Karger, Basel). 1988;23:216–24.
Emanuel D, Peppard J, Chehimi J et al. The diagnostic, prophylactic, and therapeutic uses of monoclonal antibodies to human cytomegalovirus. Transplant Proc. 1987;l9(Suppl.7):132–7.
Chou S. Neutralizing antibody responses to reinfecting strains of cytomegalovirus in transplant recipients. J Infect Dis. 1989;160:16–21.
Tsevat J, Snydman DR, Pauker SG et al. Which renal transplant patients should receive cytomegalovirus immune globulin: a cost-effectiveness analysis. Transplantation. 1991;52:259–65.
Centers for Disease Control. Outbreak of hepatitis C associated with intravenous immunoglobulin administration — United States, October 1993–June 1994. Morbid Mortal Weekly Rep. 1994;43:505–9.
Brayman KL, Dafoe DC, Smythe WR et al. Prophylaxis of serious cytomegalovirus infection in renal transplant candidates using live human cytomegalovirus vaccine. Arch Surg. 1988;123:1502–8.
Plotkin SA, Smiley ML, Friedman HM et al. Towne vaccine in the prevention of post-transplant CMV disease. Lancet. 1984;1:528–30.
Plotkin SA, Starr SE, Friedman HM et al. Vaccines for the prevention of human cytomegalovirus infection. Rev Infect Dis. 1990;12(Suppl.7):S827–38.
Plotkin SA, Starr SE, Friedman HM et al. Effect of Towne live virus vaccine on cytomegalovirus disease after renal transplant: a controlled trial. Ann Intern Med. 1991;114:525–31.
Balfour HH Jr. Welo PK, and Sach GW. Cytomegalovirus vaccine trial in 400 renal transplant candidates. Transplant Proc. 1985;17:81–3.
Spaete RR. A recombinant subunit vaccine approach to HCMV vaccine development. Transplant Proc. 1991;23(Suppl.3):90–6.
Balfour HH Jr. Chace BA, and Stapleton JC et al. A randomized, placebo-controlled trial of oral acyclovir for the prevention of cytomegalovirus disease in recipients of renal allografts. N Engl J Med. 1989;320:1381–7.
Winston DJ, Ho WG, Bartoni K et al. Ganciclovir prophylaxis of cytomegalovirus infection and disease in allogeneic bone marrow transplant recipients: results of a placebo-controlled, double-blind trial. Ann Intern Med. 1993;118:179–84.
Goodrich JM, Bowden RA, Fisher L et al. Ganciclovir prophylaxis to prevent cytomegalovirus disease after allogeneic marrow transplant. Ann Intern Med. 1993;118:173–8.
Merigan TC, Reylund DG, Keay S et al. A controlled trial of ganciclovir to prevent cytomegalovirus disease after heart transplantation. N Engl J Med. 1992;326:1182–6.
Bailey TC, Trulock EP, Ettinger NA et al. Failure of prophylactic ganciclovir to prevent cytomcgalovirus disease in recipients of lung transplants. J Infect Dis. 1992;165:548–52.
Martin M, Manez R, Linden P, et al. A prospective randomized trial comparing sequential ganciclovir-high dose acyclovir to high dose acyclovir for prevention of cytomegalovirus disease in adult liver transplant recipients. Transplantation. 1996 (In press).
Schmidt GM, Horak DA, Niland JC et al. A randomized, controlled trial of prophylactic ganciclovir for cytomegalovirus pulmonary infection in recipients of allogeneic bone marrow transplant. N Engl J Med. 1991;324:1005–11.
Goodrich JM, Mori M, Gleaves CA et al. Early treatment with ganciclovir to prevent cytomegalovirus disease after allogeneic bone marrow transplantation. N Engl J Med. 1991;235:1601–7.
Rubin RH. Preemptive therapy in immunocompromised hosts. N Engl J Med. 1991;324:1057–9.
Hibberd PL, Tolkhoff-Runin NE, Cosimi AB et al. Symptomatic cytomegalovirus disease in the cytomegalovirus antibody seropositive renal transplant recipient treated with OKT3. Transplantation. 1992;53:68–72.
Hibberd PL, Tolkhoff-Rubin NE, Conti D et al. Preemptive ganciclovir therapy to prevent cytomegalovirus disease in cytomegalovirus antibody-positive renal transplant recipients. Ann Intern Med. 1995;123:18–26.
Simmons RL, Weil R, and Tallent MB et al. Do mild infections trigger the rejection of renal allografts? Transplant Proc. 1970;2:419–23.
Griffith BP, Paradis IL, Zeevi A et al. Immunologically mediated disease of the airways after pulmonary transplantation. Ann Surg. 1988;208:371–8.
O’Grady JG, Alexander GJM, Sutherland S et al. Cytomegalovirus infection and donor/recipient HLA antigens: interdependent co-factors in pathogenesis of vanishing bile-duct syndrome after liver transplantation. Lancet. 1988;2:302–5.
Paya CV, Hermans PE, Wiesner RH et al. Cytomegalovirus hepatitis in liver transplantation: prospective analysis of 93 consecutive orthotopic liver transplantations. J Infect Dis. 1989;160:752–8.
Fryd DS, Peterson PK, Ferguson RM et al. Cytomegalovirus as a risk factor in renal transplantation. Transplantation. 1980;30:436–9.
Rubin RH, Tolkhoff-Rubin NE, Oliver D et al. Multicenter seroepidemiologic study of the impact of cytomegalovirus infection on renal transplantation. Transplantation. 1985;40:243–9.
Grattan MT, Moreno-Cabral CE, Starnes VA et al. Cytomegalovirus infection is associated with cardiac allograft rejection and atherosclerosis. J Am Med Assoc. 1989;261:3561–6.
Loebe M, Schuler S, Zais O et al. Role of cytomegalovirus infection in the development of coronary artery disease in the transplanted heart. J Heart Transplant. 1990;9:707–11.
Weimar W, Balk AH, Metselaar HJ et al. On the relation between cytomegalovirus infection and rejection after heart transplantation. Transplantation. 1991;52:162–4.
Normann SJ, Salomon DR, Leelachaikul P et al. Acute vascular rejection of the coronary arteries in human heart transplantation: pathology and correlations with immunosuppression and cylomegalovirus infection. J Heart Lung Transplant. 1991;10:674–87.
Koskinen PK, Niemenen MS, Krogerus LA et al. Cytomegalovirus infection and accelerated cardiac allograft va.sculopathy in human cardiac allografts. J Heart Lung Transplant. 1993;12:724–9.
Milne DS, Gascoigne A, Wilkes J et al. The immunohistopathology of obliterative bronchiolitis following lung transplantation. Transplantation. 1992;54:748–50.
Reinsmoen NL, Bolman RM III, Savik K et al. Are multiple immunopathogenetic events occurring during the development of obliterative bronchiolitis and acute rejection? Transplantation. 1993;55:1040–4.
Nakleh RE, Bolman RM III, Henke CA et al. Lung transplant pathology. A comparative study of pulmonary acute rejection and cytomcgaloviral infection. Am J Surg Pathol. 1991;15:1197–1201.
Smiley ML, Mar EC. Huang ES. Cytomegalovirus infection and viral induced transformation of human endothelial cells. J Med Virol. 1988;21:3667–9.
Melnick JL, Adam E, DeBakey ME. Possible role of cytomegalovirus in atherogenesis. J Am Med Assoc. 1990;263:2204–7.
Benditt EP, Barrett T, Dougall JK. Viruses in the etiology of atherosclerosis. Proc Natl Acad Sci. 1983;80:6386–9.
Fujinami RS, Nelson JA, Walker L et al. Sequence homology and immunologic cross-reactivity of human cytornegalovirus with HLA-DR beta-chain: a means for graft rejection and immunosuppression. J Virol. 1988;62:100–5.
Beck S, Barrel BG. Human cytomegalovirus incodes a glycoprotein homologous to MHC class-I antigens. Nature. 1988;331:269–72.
Hosenpud JD, Chou S, Wagner CR. Cytomeglovirus-induced regulation of major histocompalibility complex Class I antigen expression in human aortic smooth muscle cells. Transplantation. 1991;52:896–903.
Ross R. The pathogenesis of atherosclerosis — an update. N Engl J Med. 1986;314:488–500.
Saikku P, Leinonen M, Tenkanen L et al. Chronic Chlamydia pneumoniae infection as a risk factor for coronary heart disease in the Helsinki heart study. Ann Intern Med. 1992;116:273–8.
Yamashiroya HM, Ghosh L. Yang R et al. Herpesviridae in the coronary arteries and aorta of young trauma victims. Am J Pathol. 1988;130:71–9.
Grundy JE, Downes KL. Up-regulation of LFA-3 and ICAM-I on the surfaces of fibroblasts infected with cytomegalovirus. Immunology. 1993;78:405–12.
Grundy JE. Virologic and pathogenetic aspects of cytomegalovirus infection. Rev Infect Dis. 1990 12(Suppl.3):S711–19.
Rubin RH. The indirect effects of cytomegalovirus infection on the outcome of organ transplantation. J Am Med Assoc. 1989;261:3607–9.
Blanche G, Josien R, Douillard D et al. The influence of HLA A-B-DR matching on cytomegalovirus disease after renal transplantation. Transplantation. 1993;54:871–4.
Manez R, White LT, Linden P et al. The influence of HLA matching on cytomegalovirus hepatitis and chronic rejection after liver transplantation. Transplantation. 1993;55:1067–71.
von Willebrand E, Lautenschlager I, Ahonen J. Cellular activation in the graft and in blood during CMV disease. Transplant Proc. 1989;21:2080–1.
van Dorp W, Jonges E, Bruggeman CA et al. Direct induction of MHC class I. but not class II, expression on endothelial cells by cytomegalovirus infection. Transplantation. 1989;48:469–72.
Sedmark DD, Roberts WH, Stephens RE et al. Inability of cytomegalovirus infection of cultured endothelial cells to induce HLA class II antigen expression. Transplantation. 1990;49:458–62.
Ustinov JA, Loginov RJ, Bruggeman CA et al. Cytomegalovirus induces class II expression in rat heart endothelial cells. J Heart Lung Transplant. 1993;12:644–51.
Skowronski EW, Mendoza A, Smith SC Jr. et al. Detection of cytomegalovirus in paraffin-embedded postmortem coronary artery specimens of heart transplant recipients by the polymerase chain reaction: implications of cytomegalov irus association with graft atherosclerosis. J Heart Lung Transplant. 1993;12:717–23.
Rinaldo CR Jr. Black PH, and Girsch MS. Interaction of cytomegalovirus with leukocytes from patients with mononucleosis due to cytomegalovirus. J Infect Dis. 1977;136:667–78.
Levin MJ, Rinaldo CR Jr. Leary PL et al. Immune response to herpesvirus antigens in adults with acute cytomegalovirai mononucleosis. J Infect Dis. 1979;140:851–7.
Carney WP, Hirsch MS. Mechanisms of immunosuppression in cytomegalovirus mononucleosis. II. Virus-monocyte interactions. J Infect Dis. 1981;144:47–54.
Schrier RD, Rice GPA. Oldstone MBA. Suppression of natural killer cell activity and T cell proliferation by fresh isolates of human cytomegalovirus. J Infect Dis. 1986;153:1084–91.
Dummer JS, Ho M, Rabin BP et al. The effect of cytomegalovirus and Epstein-Barr virus infection on T-lymphocyte subsets in cardiac transplant patients on cyclosporin. Transplantation. 1984;38;433–5.
Peterson PK, Balfour HH, Marker SC et al. Cytomegalovirus disease in renal allograft recipients: a prospective study of the clinical features, risk factors and impact on renal transplantation. Medicine [Baltimore]. 1980;59:283–300.
Rand KH, Pollard RB, Merigan TC. Increased pulmonary superinfections in cardiac-transplant patients undergoing primary cytomegalovirus infection. N Engl J Med. 1978;298:951–3.
Gelmann EP, Clanton DJ, Jariwalla RJ et al. Characterization and location of myc homologous sequences in human cytomegalovirus DNA. Proc Natl Acad Sci USA. 1983;80:5107–11.
Penn I. Kaposi’s sarcoma in renal transplant recipients. Transplantation. 1979;27:8–11.
Hanto DW, Frizzera G, Purtilo D. Clinical spectrum of lymphoproliferative disorders in renal transplant recipients and evidence for the role of Epstein Barr virus. Cancer Res. 1981;41:4253–61.
Purtilo D, Saemundsen AK, Sakamoto K. Documentation of Epstein-Barr virus infection in immunodeficient patients with life-threatening lymphoproliferative diseases by Epstein-Barr complementary RNA/DNA and viral DNA/DNA hybridization. Cancer Res. 1981;41:4226–36.
Ho M, Miller G, Atchison RW. Epstein-Barr virus infections and DNA hybridization studies in post-transplantation lymphoma and lymphoproliferative lesions: the role for primary infection. J Infect Dis. 1985;152:876–86.
Ho M, Jaffe R, Miller G. The frequency of Epstein-Barr virus infection and associated lymphoproliferative syndrome after transplantation and its manifestation in children. Transplantation. 1988;45:719–27.
Weintraub J, Warnke RA. Lymphoma in cardiac allotransplant recipients: clinical and histological features and immunologic phenotype. Transplantation. 1982;33:347–51.
Bieber CP, Hebersling RL, Jamieson SW. Lymphoma in cardiac transplant recipients: association with the use of cyclosporin A, prednisone, and anti-thymocyte globulin. In: Purtilo DT, editor. Immune deficiency and cancer: Epstein-Barr virus and lymphoproliferative malignancies. New York: Plenum; 1984;309–20.
List AF, Greco FA, Vogler LB. Lymphoproliferative disease in immunocompromised hosts: the role of Epstein-Barr virus. J Clin Oncol. 1987;5:1673–89.
Straus SE, Cohen JI, Tosato G et al. Epstcin-Barr virus infection: biology, pathogenesis, and management. Ann Intern Med. 1993;118:45–58.
Stephaman E, Gruber SA, Dunn DL et al. Posttransplant lymphoproliferative disorders. Transplant Rev. 1991;5:120–9.
Swinnen LJ, Costanzo-Nordin MR. Fisher SG et al. Increased incidence of lymphoproliferative disorder after immunosuppression with the monclonal antibody OKT3 in cardiac transplant recipients. N Engl J Med. 1990;323:1723–8.
Armitage JM, Kormos RL, Stuart RS et al. Posttransplant lymphoproliferativc disease in thoracic organ transplant patients: ten years of cyclosporin-based immunosuppression. J Heart Lung Transplant. 1991;10:877–87.
Emery RW, Lake KD. Post-transplantation lymphoproliferative disorder and OKT3. (Letter) N Engl J Med. 1991;324:1437.
Brouwer RML, Balk AHMM, Weimar W. Post-transplantation lymphoproliferative disorder and OKT3. (Letter) N Engl J Med. 1991;324:1437.
Cosimi AB, Rubin RH. Post-transplantation lymphoproliferative disorder and OKT3. (Letter) N Engl J Med. 1991;324:1438.
Fingeroth JD, Weiss JJ, Tedder TF et al. Epstein-Barr virus receptor of human B lymphocytes is the C3d receptor CR2. Proc Natl Acad Sci USA. 1984;81:4510–14.
Frade R, Barel M, Ehlin-Eriksson B et al. gp l40, the C3d receptor of human B lymphocytes, is also the Epstein-Barr virus receptor. Proc Natl Acad Sci USA. 1985;82:1490–3.
Schooley RT. Epstein-Barr virus (infectious mononucleosis). In: Mandell GL, Bennett JE, Dolin R, editors: Principles and practice of infectious diseases, 4th edn. New York: Churchill Livingstone: 1995;1364–77.
Diller J, Kallin B. The Epstein-Barr virus proteins. Adv Cancer Res. 1988;50:95–158.
Sixbey JW, Nedrud JG, Raab-Traub N et al. Epstein-Barr virus replication in oropharyngeal epithelial cells. N Engl J Med. 1984;310:1225–30.
Preiksaitis JK, Diaz-Mitoma F, Mirzayans F et al. Quantitative oropharyngeal Epstein-Barr virus shedding in renal and cardiac transplant recipients: relationship to immunosuppressive therapy, serologic responses, and the risk of posttransplant lymphoproliferative disorder. J Infect Dis. 1992;166:986–94.
Sixbey JW, Shirley P, Sloas M et al. A transformation-incompetent, nuclear antigen 2-depleted Epstein-Barr virus associated with replicative infection. J Infect Dis. 1991;163:1008–15.
Sixbey JW, Shirley P, Chesney PJ et al. Detection of a second widespread strain of Epstein-Barr virus. Lancet. 1989;2:761–5.
Randhawa PS, Jaffe R, Demetris AJ et al. Expression of Epstein-Barr virusencoded small RNA (by the EBER-1 gene) in liver specimens from transplant recipients with post-transplantation lymphoproliferative disease. N Engl J Med. 1992;327:1710–14.
Basgosz N, Hibberd PL, Tolkhoff-Rubin NE et al. Possible role of cytomegalovirus disease in the pathogencsis of post-transplant lymphoproliferative disorder. Abstract P-l-50, 12th Annual Meeting. American Society of Transplant Physicians. Houston. 1993.
Vieira P, DeWaal-Malefyt R, Dang MN et al. Isolation and expression of human eytokine inhibiting factor cDNA clones: homology to Epstein-Barr open-reading frame BCRF-I. Proc Natl Acad Sci USA. 1991;88:1172–6.
Hanto DW, Gajl-Peczalska KJ, Frizzera G et al. Epstein-Barr virus (EBV)-induced polyclonal and monoclonal B cell lymphoproliferative diseases occurring after renal transplantation: clinical, pathologic, and virological findings and implications for therapy. Ann Surg. 1983;198:356–69.
Ren KC, Chan SH. Possible enhancement of Epstein-Barr virus infections by the use of OKT3 in transplant recipients. Transplantation. 1988;45:988–9.
Cheeseman SH, Henle W, Ruhin RH et al. Epstein Barr virus infection in renal transplant recipients: Effects of anti-thymocyte globulin and interferon. Ann Intern Med. 1970;193:39–44.
Jones JF, Shurin S, Abramowsky C et al. T cell lymphomas containing Epstein-Barr viral DNS in patients with chronic Epstein-Barr virus infections. N Engl J Med. 1988;318:733–41.
Wiles HB, Laver J, Baum D. T cell lymphoma in a child after heart transplantation. J Heart Lung Transplant. 1994;13:1019–23.
Telenti A, Smith TF, Ludwig J et al. Epstein-Barr virus and persistent graft dysfunction after liver transplantation. Hepatology. 1991;14:282–6.
Hanto DW, Frizzera G. Gajl-Peczalska KJ. Epstein-Barr virus-induced B cell lymphoma after renal transplantation: acyclovir therapy and transition from polyclonal to monoclonal B cell proliferation. N Engl J Med 1982;306:913–18.
Starzl TE, Porter KA, Iwatsuki S et al. Reversibility of lymphomas and lymphoproliferative lesions developing under cyclosporin-steroid therapy. Lancet. 1984;17:583–7.
Hanlo DW, Frizzera G, Gajl-Peczalska KJ et al. Acyclovir therapy of Epstein Barr virus induced post-transplant lymphoproliferative disease. Transplant Proc. 1985;17:89–93.
Sullivan JL, Byron KS, Brewsler FE et al. Treatment of life-threatening Epstein-Barr virus infection with acyclovir. Am J Med. 1982;73(Suppl.1A): 262–6.
Pirsch JD, Stralta RJ, Sollinger HW et al. Treatment of severe Epstein-Barr virusinduced lymphoproliferative syndrome with gancielovir: two cases after solid organ transplantation. Am J Med. 1989;86:241–4.
Blanche S, LeDiest F, Veber F et al. Treatment of severe Epstein-Barr virusinduced polyclonal B-lymphocyle proliferation by anti-B cell monoclonal antibodies: two cases after HLA-mismatched bone marrow transplantation. Ann Intern Med. 1988;108:199–203.
Fischer A, Blanche S, LeBidois J et al. Anti-B cell monoclonal antibodies in the treatment of severe B cell lymphoproliferative syndrome following bone marrow and organ transplantation. N Engl J Med. 1991;324:1451–6.
Shapiro RS, Chauvenet A, McGuire W et al. Treatment of B cell lymphoproliferative disorders with interfcron alfa and intravenous gamma globulin. (Letter) N Engl J Med. 1988;318:1334.
Walker RC, Marshall WF, Strickler JG et al. Pretransplantation assessment of the risk of lymphoproliferative disorder. Clin Infect Dis. 1995;20:1346–53.
Douglas RG, Anderson S, Weg JG et al. Herpes simplex virus pneumonia: occurrence in an allotransplanted lung. J Am Med Assoc. 1969;210:902.
Smyth RL, Higenbottam TW, Scott JP et al. Herpes simplex virus infection in heart-lung transplant recipients. Transplantation. 1990;49:735–9.
Straus SE, Smith HA, Brickman C et al. Acyclovir for chronic mucocutancous herpes simplex virus infection in immunosuppressed patients. Ann Intern Med. 1982;96:270–7.
Dummer JS, Armstrong J, Somers J et al. Transmission of infection with herpes simplex virus by renal transplantation. J Infect Dis. 1987;155:202–6.
Loxley RM, Flournoy N, Sullivan KM et al. Infection with varicella-zoster virus after marrow transplantation. J Infect Dis. 1986;6:1172–81.
Straus SE, Ostrove JM, Inchauspe G. Varicella-zoster virus infections: biology, natural history, treatment and prevention. Ann Intern Med. 1988;108:221–37.
Centers for Disease Control and Prevention Varicella-zoster immune globulin for the prevention of chickenpox. Recommendations of the immunization practices advisory committee. Ann Intern Med. 1984;100:859–65
Forghani B, Schmidt NJ, Dennis J. Antibody assays for varicella-zoster virus: Comparison of enzyme immunoassay with neutralization, immune adherence hemagglutination. and complement fixation. J Clin Microbiol 1978;8:545–52.
Feldhoff CM, Balfour HH Jr. and Simmons RL. et al. Varicella in children with renal transplants. J Pediatr. 1981;98:25–31.
Lynfield R, Herrin JT, Rubin RH. Varicella in pediatric renal transplant recipients. Pediatrics. 1992;90:216–20.
Whitley RJ. Varicella zoster virus. In: Mandell GL, Bennett JK. Dolin R. editors. Principles and practice of infectious diseases. 4th edn. New York: Churchill Livingstone: 1995;1345–51.
Huff JC, Bean B, Balfour HH et al. Therapy of herpes zoster with oral acyclovir Am J Med. 1988;85:84–9.
Wood MJ, Bean PH, McKendrick MW et al. Efficacy of oral acyclovir treatment of herpes zoster. Am J Med. 1988;85:79–83.
Prober CG, Kirk LE, Keeney RE. Acyclovir therapy of chickenpox in immunosuppressed children: a collaborative study. J Pediatr 1982;101:622–5.
Balfour HH Jr. Bean B, and Laskin OL et al. Acyclovir halts the progression of herpes zoster in immunocompromised patients. N Engl J Med. 1983;308:1448–53.
Whitley RJ, Gnann JW. Acyclovir: a decade later. N Engl J Med. 1992;327:782–9.
Lusso P, Markham PD, Tschachler P et al. In vitro cellular tropism of human B-lymphotropic virus (human herpesvirus-6). J Exp Med. 1988;167:1659–70.
Wrzos H, Gibbons J, Abt PL et al. Human herpesvirus 6 in monocytes of transplant recipients. Lancet 1990;335:486–7.
Brown NA, Sumaya CV, Liu CR et al. Fall in human herpersvirus 6 seropositivity with age. (Letter) Lancet. 1988;2:396.
Efstathiou S, Gompels UA, Craxton MA et al. DNA homology between a novel human herpesvirus (HHV-6) and human cytomegalovirus. (Letter) Lancet 1988;1:63–4.
Morris DJ, Littler E, Arrand JR et al Human herpesvirus-6 infection in renaltransplant recipients. N Engl J Med. 1989;320:1560–1.
Yamanishi K, Okuno T, Shiraki K et al. Identification of human herpesvirus-6 as a causal agent for exanthem subitum. Lancet. 1988;1:1065–7.
Krueger GRF. Human herpesvirus-6 infection and disease. (Letter) Lancet 1988;2:518.
Spira TJ, Bozeinan LH, Sanderliu KC et al. Lack of correlation between human herpesvirus-6 infection and the course of human immunodeficiency virus infection. J Infect Dis. 1990;161:567–70.
Robinson WS. Hepadnaviridae: hepatitis B virus and hepatitis D virus. In: Mandell GL. Bennett JE, Dolin R. editors. Principles and practice of infectious diseases, 4th edn. New York: Churchill Livingstone: 1995;1406–39.
Katkov WN, Rubin RH. Liver disease in the organ transplant recipient: etiology, clinical impact, and clinical management. Transplant Rev. 1991;5:200–8.
LaQuaglia MP, Tolkhoff-Rubin NE, Dienstag JL et al. Impact of hepatitis on renal transplantation. Transplantation. 1981;32:504–7.
Alter MJ, Evatt BL, Margolis HS et al. Public health service interagency guidelines for screening donors of blood, plasma, organs, tissues, and semen for evidence of Hepatitis B and Hepatitis C. Morbid Mortal Weekly Rep. 1991;40(RR-4):1.
Szmuness W. Hepatocellular carcinoma and the hepatitis B virus, evidence for a causal association. Progr Med Virol. 1978;24:40.
Hollinger FB, Werch J, Melnick JL. A prospective study indicating that doubleantibody radioimmunoassay reduces the incidence of post-transfusion hepatitis B. N Engl J Med. 1974;290:1104–9.
Alter HJ, Holland PV, Purcell RH. The emerging pattern of post-transfusion hepatitis. Am J Med Sci. 1975;270:329.
Hoofnagle JH, Seeff LB, Bales ZB et al. The Veterans Administration Cooperative Hepatitis Study Group. Type B hepatitis after transfusion with blood containing antibody to hepatitis B core antigen. N Engl J Med. 1978;298:1379–83.
Nagington J, Cossart YE, Cohen BJ. Reactivation of hepatitis B after transplantation operations. Lancet. 1977;1:558.
Wands JR. Chura CM, Roll FJ et al. Serial studies of hepatitis associated antigen and antibody in patients receiving anti-tumor chemotherapy for myeloproliferative and lymphoproliferative disorders. Gastroenterology. 1975;68:105.
Rao KV, Anderson RC. Long term results and complications in renal transplant recipients. Observations in the second decade. Transplantation. 1988;45:45–52.
Rao KV, Kasiske BL, Anderson WR. Variability in the morphological spectrum and clinical outcome of chronic liver disease in hepatitis B-positive and B-negative renal transplant recipients. Transplantation. 1991;51:391–6.
Parfrey PS, Forbes RD, Hutchinson TA et al. The clinical and pathological course of hepatitis B liver disease in renal transplant recipients. Transplantation. 1984;37:461–6.
Harnett JD, Zeldis JB, Parfrey PS et al. Hepatitis B disease in dialysis and transplant patients. Further epidemiologic and serologic studies. Transplantation. 1987;44:369–76.
Fauley CK, Mijch A, Gust ID et al. The increased risk of fatal liver disease in renal transplant patients who are hepatitis Be antigen and/or HBV DNA positive. Transplantation. 1991;52:497–500.
Dummer JS, Ho M, Simmons RL. Infections in solid organ transplant recipients. In: Mandell GL, Bennett JE, Dolin R, editors. Principles and practice of infectious diseases. 4th edn. New York: Churchill Livingstone; 1995;2722–32.
Perillo RP, Schiff ER, Davis GL et al. A randomized, controlled trial of interferon alfa-2b alone and after prednisone withdrawal for the treatment of chronic hepatitis B. N Engl J Med. 1990;323:295–301.
Samuel D, Bismuth A, Mathieu D et al. Passive immunoprophylaxis after liver transplantation in HBsAg-positive patients. Lancet. 1991;1:813–15.
Yu MC, Tong MJ. Coursaget P et al. Prevalence of hepatitis B and C viral markers in black and white patients with hepatocellular carcinoma in the United States. J Natl Cancer Inst. 1990;82: 1038–41.
Pereira BJG, Milford EL, Kirkman RL et al. Transmission of hepatitis C by organ transplantation. N Engl J Med. 1991;325:454–60.
Pereira BJG, Milford EL, Kirkman RL et al. Prevalence of hepatitis C virus RNA in organ donors positive for hepatitis C antibody and in the recipients of their organs. N Engl J Med. 1992;327:910–15.
Roth D, Fernandez JA, Babischkin S et al. Detection of hepatitis C virus infection among cadaver organ donors: Evidence for low transmission of disease. Ann Intern Med. 1992;117:470–5.
Vincenti F, Lake J. Wright TP et al. Nontransmission of hepatitis C from cadaveric kidney donors to transplant recipients. Transplantation. 1993;55:674–5.
Diethelm AG, Roth D, Ferguson RM et al. Transmission of HCV by organ transplantation. (Letter). N Engl J Med. 1992;326:410–11.
Pirsch JD, Belzer FO. Transmission of HCV by organ transplantation. (Letter) N Engl J Med. 1992;326:412.
Martinez E, Marcos A. Transmission of HCV by organ transplantation. (Letter) N Engl J Med. 1992;326:412.
Zeldis JB, Dienstag JL, Gale RP. Aplastic anemia and non-A, non-B hepatitis. Am J Med. 1983;74:64–8.
Tzakis AG, Arditi M, Whitington PF et al. Aplastic anemia complicating orthotopic liver transplantation for non-A. non-B hepatitis. N Engl J Med. 1988;319:393–6.
Stock PG, Steiner ME, Freese D et al. Hepatitis-associated aplastic anemia after liver transplantation. Transplantation. 1987;43:595–7.
Young NS. Flaviviruses and bone marrow failure. J Am Med Assoc. 1990;263:3065–8.
Farci P, Alter HJ, Wong D et al. A long-term study of hepatitis C virus replication in non-A. non-B hepatitis. N Engl J Med. 1991;325:98–104.
Silva AE, Hosein B, Boyle RW et al. Diagnosis of chronic hepatitis C: comparison of imnuinoussays and the polymerase chain reaction. Am J Gastroenterol. 1994;89:493–6.
Lok ASF, Chien D, Choo Q-L et al. Antibody response to core, envelope, and nonstructural hepatitis C virus antigens: comparison ot immunocoinpetent and immunosuppressed patients Hepatology. 1993;18:497 502.
Uyttendaele S, Claeys H, Mertens W et al. Evaluation of thirdgeneration screening and confirmatory assays for HCV-antibodies. Vox Sang. 1994;66:122–9.
Iwarson S, Norkrans G, Wejstal R. Hepatitis C: natural history of a unique infection. Clin Infect Dis. 1995;20:1361–70.
diBisceglie AM, Martin P, Kassianides C et al. Recombinant interferon alfa therapy for chronic hepatitis C. A randomized, double-blind, placebo-controlled trial. N Engl J Med. 1989,321:1506–10.
Shindo M, diBisceglie AM, Cheung L et al. Decrease in serum hepatitis C viral RNA during alpha-interferon therapy for chronic hepatitis C. Ann Intern Med. 1991;115:700–4.
Reichard O, Andersson J, Schvarez R et al. Ribavirin treatment tor chronic hepatitis C. Lancet. 1991;337:1058–61.
diBisceglie AM, Shindo M, Fong T-L et al. A pilot study of ribavirin therapy for chronic hepatitis C. Hepatology. 1992;16:649–54.
Chemello L, Cavalletto L, Bernardinello E et al. Randomized trial comparing interferon alfa or ribavirin alone or in combination for the treatment of chronic hepatitis C. In: VI International Symposium on Viral Hepatitis, February 1994, Madrid (abstract).
Prince AM, Brotman B, Huima T et al. Immunity in hepatitis C infection. J Infect Dis. 1992;165:438–43.
Farci P, Alter HJ, Govindarajan S et al. Lack of protective immunity against reinfection with hepatitis C virus. Science. 1992;258:135–40.
Keating MR, Wilhelm MP, Walker RC. Strategies for prevention of infection alter cardiac transplantation. Mayo Clin Proc. 1992;67:676–84.
Milfred SK, Lake KD, Anderson DJ et al. Practices of cardiothoracic transplant centers regarding hepatitis C seropositive candidates and donors. Transplantation. 1994;57:568–72.
Lake KD, Milfred S. Reutzel T et al. Practices of cardiothoracic transplant centers regarding hepatitis C+ candidates and donors — a follow-up survey. J Heart Lung Transplant. 1995;14:570.
Wright TL, Hepatitis C and other forms of NANB hepatitis in transplantation. Presented at the North American Transplant Infectious Disease Symposium, Boston: 1993.
Kumar P, Pearson JE, Martin DH et al. Transmission of human immunodeficiency virus by transplant of a renal allograft with development of the acquired immunodeficiency syndrome. Ann Intern Med. 1987;106:244–5.
Milgrom M, Esquanazi V, Fuller L et al. AIDS in a transplant patient. Transplant Proc. 1985;17:75–6.
Bowen PA III, Lobel SA, Caruana RJ et al. Transmission of human immunodeficiency virus (HIV) by transplantation: clinical aspects and time course analysis of viral antigenemia and antibody production. Ann Intern Med. 1988;1046–8.
Carbone LG, Cohen DJ, Hardy MA et al. Determination of acquired immunodeficiency syndrome (AIDS) alter renal transplantation. Am J Kidney Dis. 1988;10:387–92.
Rubin RH, Jenkins RL, Byers WS Jr et al. The acquired immunodeficiency syndrome and transplantation. Transplantation. 1987;44:1–4.
Bouscarat F, Samuel D, Simon S et al. An observational study of 11 French liver transplant recipients infected with human immunodeficiency virus type I. Clin Infect Dis. 1994;19:854–9.
Ericc A, Rhame FS, Heussner RC et al. Human immunodeficiency virus infection in patients with solid-organ transplants: report of five cases and review. Rev Infect Dis. 1991;13:537–47.
Dummer JS, Erb S, Breinig MK et al. Infection wilh human immunodeficiency virus in the Pittsburgh transplant population: a study of 583 donors and 1043 recipients. 1981–1986. Transplantation. 1989;47:134–40.
Simonds RJ, Holmberg SD, Hurwitz RL et al. Transmission of human immunodeficiency virus type 1 from a seronegative organ and tissue donor. N Engl J Med. 1992;326:726–32.
Perez G, Ortiz-Interian C, Bourgoignic JJ et at, HIV-1 and HTLV-1 infection in renal transplant recipients. J AIDS. 1990;3:35–40.
Quarto M, Germinario C, Fontanu A et al. HIV transmission through kidney transplantation from a living related donor. (Letter) N Engl J Med. 1989;320:1754.
Imagawa DT, Lee MH, Wolinsky SM et al. Human immunodeficiency virus type I infection in homosexual men who remain seronegative for prolonged periods. N Engl J Med. 1989;320:1458–62.
Wolinsky SM, Rinaldo CR, Kwok S et al. Human immunodeficiency virus type I (HIV-1) infection a median of 18 months before a diagnostic Western blot: evidence from a cohort of homosexual men. Ann Intern Med. 1989;111:961–72.
Larson CJ, Taswell HF, Human T cell leukemia virus type I (HTLV-I) and blood transfusion. Mayo Clin Proc. 1988;63:869–75.
Minamoto GY, Gold JWM, Scheinberg DA et al. Infection with human T cell leukemia virus type-I in patients with leukemia. N Engl J Med 1988;318:219–22.
Ratner L, Poiesz BJ, Leukemias associated wilh human T cell lymphotropic virus type I in a non-endemic region. Medicine (altimore). 1988;67:401–22.
Wcinberg JB, Blazey DL, Janssen RS et al. Human T cell lymphotropic virus I and adult T cell leukemia: a report of a cluster in North Carolina. Am J Med 1988;85:51–8.
Broder S, Pathogenic human retroviruses. (Editorial) N Engl J Med 1988;318:243–5.
Quinn TC, Zacarias FK, and St John RK. HIV and HTLV I infections in the Americav a regional perspective. Medicine (Baltimore). 1989;68:189–208.
Hollsberg P, Hafler DA. Pathogenesis of disease induced by human lymphotropic virus type I infection. N Engl J Med. 1993;328: 1173–81.
Gout O, Baulac M, Gessuin A et al. Rapid development of myelopathy after HTLV-I infection acquired by transfusion during cardiac transplantation. N Kngl J Med. 1990;322:383–8.
Rosenblatt JD, Guide DW, Wachsman W et al. A second isolate of HTLV-I1 associated wilh atypical hairy-cell leukemia. N Engl J Med. 1986;315:372–7.
Khabbaz RF, Onoralo IM, Cannon RO et al. Seroprevalence of HTLV-I and HTLV-2 among intravenous drug users and persons in clinics for sexually transmitted diseases. N Engl J Med. 1992;326:375–9.
Demeter LM, JC, BK. and other polyomaviruses; progressive multitocal leukoencephalopathy. In: Mandell GL, Bennett JE, Dolin R. editors. Principles and practice of infectious diseases, 4th edn. New York: Churchill Livingstone; 1995;1400–6.
Flomenbaum MA, Jarcho JA, Schoen FJ. Progressive multifocal leukoencephalopathy fifty-seven months after heart transplantation. J Heart Lung Transplant. 1991;10:888–93.
Shields AF, Hackman RC, Fife KH et al. Adenovirus infections in patients undergoing bone-marrow transplantation. N Engl J Med. 1985;312:529–33.
Myerowitz RL, Stalder H, Oxman MN et al. Fatal disseminated adenovirus infection in a renal transplant recipient. Am J Med. 1975;59:591–8.
Landry ML, Fong CKY, Neddermann K. Disseminated adenovirus infection in an immunocumpromiscd host. Am J Med. 1987;83:555–9.
Koneru B, Jaffe R, Esquivel CO et al. Adenoviral infections in pediatric liver transplant recipients. J Am Med Assoc. 1987;258:489–92.
Doud JR, Hinhamp T, Garrily ER Jr. Respiratory syncytial virus pneumonia in a lung transplant recipient: case report. J Heart Lung Transplant. 1992;l1:77–9.
Sinnott JT IV. Respiratory syncytial virus pneumonia in a cardiac transplant recipient. J Infect Dis. 1988;158:650–1.
Janner D, Bork J, Baum M et al. Severe pneumonia after heart transplantation as a resull of parvovirus B 19. J Heart Lung Transplant. 1994;13,336–8.
Frankel JK. Microbiology of Toxoplasma gondii. In: Hammond DH. Long PL. editors. Parasite life cycle and immunology. Baltimore, MD: University Park Press; 1973:343.
Shafer N. Toxoplasmosis. NY State J Med. 1975;75:1044–61.
Riemann HP, Meyer ME, Theiss JH et al. Toxoplasmosis in an infant fed unpastcurized goat’s milk. J Pediatr. 1975;87:573–6.
Miller MJ, Aronson WJ, Remington JS. Late parasitemia in asymptomatic cases of acquired toxoplasmosis. Ann Intern Med. 1969;71:139–45.
Ruskin J, Remington JS. Toxoplasmosis in the compromised host. Ann Intern Med. 1976;84:193–9.
Anderson R, Sandberg T, Berglin E et al. Cytomegalovirus infections and toxoplasmosis in heart transplant recipients in Sweden. Scand J Infect Dis. 1992;24;411–17.
Waser M, Leonardi L, Mohasci P et al. Toxoplasmosis in the heart transplant patient. Ther Umseh. 1990;47:152–6.
Rubin RH, Tulkhoff-Rubin NE. Opportunistic infections in renal allograft recipients. Transplant Proc. 1988;20(Suppl.8): 12–18.
Molliman RH, Johnson JD, Adams S et al, Toxoplasmusis and heart transplantation. J Heart Lung Transplant. 1991;10:608–10.
Wreghitt TG, Gray JJ, Balfour AH. Tovoplasmosis in heart and heart and lung transplant recipients. J Clin Pathol. 1986;39:1135–9.
Feldman H. Toxoplasmosis: an overview. Bull NY Acad Med. 1974;50:110–27.
Luft BJ, Naot Y, Araujo FG et al. Primary and reactivation Toxoplasma infection in patients with cardiac transplants: clinical spectrum and problems in diagnosis in a defined population. Ann Intern Med. 1983;99:27–31.
Shepp DH, Haekman RC, Conley FK et al. Toxoplasma gondii reactivation identified by detection of parasitemia in tissue culture. Ann Intern Med. 1985;103:218–21.
Beaman M, McCabe RE, Wong S-Y, Remington JS. Toxoplasma gondii. In: Mandell GL, Bennett JE, Dolin R, editors. Principles and practice of infectious diseases. 4th edn. New York: Churchill Livingstone; 2455–72.
Wagner FM, Reichenspurner H, Uberfuhr P et al. Toxoplasmosis after heart transplantation: diagnosis by endomyocardial biopsy. J Heart Lung Transplant. 1994;13:916–18.
Andreone PA, Olivari MT, Elick B et al. Reduction of infectious complications following heart transplantation with triple-drug immunolherapy. J Heart Lung Transplant. 1986;5:13–19.
LeClair RA. Transplantation pneumonia, associated with Pneumocystis carinii. among recipients of cardiac transplants. Am Rev Resp Dis. 1969;100:874–5.
Narins B, Jessup M. Pneumocystis carinii pneumonia after heart transplantation: a growing problem. J Heart Transplant. 1990;9:67.
Olsen SO, Renlund DG, O’Connell JB et al. Prevention of Pneumocystis pneumonia in cardiac transplant recipients by trimethoprim-sulfamethoxazole. Transplantation. 1993;56:359–62.
Kramer MR, Stoehv C, Lewiston NJ et al. Trimethoprim-sulfamethoxazole prophylaxis for Pneutnocystis carinii infections in heart-lung and lung transplantation: how effective and for how long? Transplantation. 1992;53:586–9.
Gryzan S, Paradis IL, Zeevi A et al. Unexpectedly high incidence of Pneumocystis carinii infection after lung-heart transplantation. Am Rev Resp Dis. 1988;137:1268–74.
Hughes WT, McNabb PC, Makres TD et al. Efficacy of trmethoprim and sulfamethoxazole in the prevention and treatment of Pneumocystis carinii pneumonias. Antimicrob Agents Chcmother. 1974;5:289–93.
Hughes WT, Kuhn S, Chaudhary S. Successful chemoprophylaxis for Pneumocystis carinii pneumonitis. N Engl J Med. 1977;297:1419–26.
Hughes WT, Rivera GK, Schell MJ et al. Successful intermittent chemoprophylaxis for Pneumocystis carinii pneumonitis. N Engl J Med. 1987;316:1627–32.
Sepkowitz KA, Brown AE, Armstrong D. Pneumocystis carinii pneumonia without acquired immunodeficiency syndrome. (Editorial) Arch Intern Med. 1995;155:1125–8.
Sepkowitz KA. Pneumocystis carinii pneumonia in patients without AIDS. Clin Infect Dis. 1993;17(Suppl.2);S416–22.
Sepkowitz KA, Brown AE, Telzak AE et al. Pneumocystis carinii pneumonia among patients without AIDS in a cancer hospital. J Am Med Assoc. 1992;267:832–7.
Graham BS, Tucker WS. Opportunistic infections in endogenous Cushing’s syndrome. Ann Intern Med. 1984;101:334–8.
Sanford JP, Sande MA, Gilbert DN et al. The Sanford Guide to HIV/AIDS Therapy. Dallas. TX: Antimicrobial Therapy Inc.: 1994;68–9.
Masur H, Gill VJ, Ognibene FP et al. Diagnosis of Pneumocystis pneumonia by induced sputum technique in patients without the acquired immunodeficiency syndrome. Ann Intern Med. 1988;109:755–6.
Kovacs JA, Ng VL, Masur H et al. Diagnosis of Pneumocystis carinii pneumonia: improved detection in sputum with use of monoclonal antibodies. N Engl J Med. 1988;318:589–93.
While MJ. Prevention of infections in patients with neoplastic disease: use of a historical model for developmental strategies. Clin Infect Dis. 1993;17(Suppl.2):S359–67.
Genta RM. Global prevalence of strongyloidiasis: critical review with epidemiologic insights into the prevention of disseminated disease. Rev Infect Dis. 1989;11:755–67.
Control of Chagas disease: report of a WHO expert committee. WHO Tech Rep Ser. 1991;811:27–37.
Schmunis GA. Trypanosoma cruzi, the etiologic agent of Chagas disease: status in the blood supply in endemic and non-endemic countries Transfusion. 1991;31:547–57.
Carrasco R, Miguel H, Camacho C et al. Prevalence of Trypanosoma cruzi infection in blood banks of seven departments of Bolivia. Mem Inst Oswaldo Cruz. 1990;85:69–73.
Kirchhoff LV. American trypanosomiasis (Chagas’ disease) a tropical disease now in the United States. N Engl J Med. 1993;329:639–44.
Chocair PR, Amato Neto V, Sabbaga E et al. Aspectos clinicodiagnosticos relativos a fase aguda da doença de Chagas. em pacientes submetidos a transplante de rim e immunossuprimidos. Rev Soc Brasil Med Trop. 1985;18:43–5.
Gottcsdicner KM. Transplanted infections: donor-to-host transmission with the allograft. Ann Intern Med. 1989;110:1001–6.
Figueiredo JF, Martinez R, da Costa JC et al. Transmission of Chagits disease through renal transplantation: report of a case. Trans R Soc Trop Med Hyg. 1990;84:61–2.
Landivar WHC, Nakasa T, Tachibana H et al. Seropositivity to Trypanosoma cruzi in blood donors in Santa Cruz. Bolivia. (Letter) J Infect Dis. 1992;166:1464–5.
Grant IH, Gold WJM, Winner M et al. Transfusion-associated acute Chagas disease acquired in the United States. Ann Intern Med. 1989;111:849–51.
Geiseler PJ, Ito JI, Tegtmeier BR et al. Fulminant Chagas disease (CD) in bone marrow transplantation (BMT). In: Program and abstracts of the 27th Interscience Conference on Antimicrobial Agents and Chemotherapy. New York, 4–7 October 1987. Washington. DC: American Society for Microbiology: 1987;169 (abstract).
Nickerson P, Orr P, Schroeder M-L et al. Transfusion-associated Trypanosoma cruzi infection in a non-endemic area. Ann Intern Med. 1989;111:851–3.
Grant IH, Gold JW, Wittner M et al. Transfusion-associated acute Chagas disease acquired in the United States. Ann Intern Med. 1989;11:849–51.
Stolf NA, Higushi L, Boechi E et al. Heart transplantation in patients with Chagas’ disease cardiomyopathy. J Heart Transplant. 1987;6:307–12.
Bocchi EA, Bellotti G, Uip D et al. Long-term follow-up after heart transplantation in Chagas’ disease. Transplant Proc. 1993;25:1329–30.
Libow LF, Beltrani VP, Silvers DN et al. Post-cardiac transplant reactivation of Chagas’ disease diagnosed by skin biopsy. Cutis. 1991;48:37–40.
Texeira ARL, Silva R, Cunha Neto E et al. Malignant non-Hodgkin’s lymphomas in Trypanosoma cruzi-infectcd rabbits treated with nitroarenes. J Comp Pathol. 1990;103:37–48.
Current WL, Reese NC, Ernst JV et al. Human cryptosporidiosis in inimunocompctent and immunodeficient persons: studies of an outbreak and experimental transmission. N Engl J Med. 1983;308:1252–7.
Cryptosporidiosis: assessment of chemotherapy of males with acquired immune deficiency syndrome (AIDS). Morbid Mortal Weekly Rep. 1982;31:589–92.
Black RE. Dykes AC. Sinclair SP et al. Giardiasis in day care centers: evidience of person-to-person transmission. Pediatrics. 1977;60:486–91.
Collier AC, Miller RA, Meyers JD. Cryptosporidiosis after marrow transplantation: Person-to-person transmission and treatment with spiramycin. Ann Intern Med. 1984;101:205–6.
Felman YM, Ricciardi NB. Sexually transmitted enteric diseases. Bull NY Acad Med. 1979;55:533–9.
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 1996 Kluwer Academic Publishers
About this chapter
Cite this chapter
Love, K. (1996). Infection in Relation to Thoracic Transplantation. In: Cooper, D.K.C., Miller, L.W., Patterson, G.A. (eds) The Transplantation and Replacement of Thoracic Organs. Springer, Dordrecht. https://doi.org/10.1007/978-0-585-34287-0_32
Download citation
DOI: https://doi.org/10.1007/978-0-585-34287-0_32
Publisher Name: Springer, Dordrecht
Print ISBN: 978-0-7923-8898-2
Online ISBN: 978-0-585-34287-0
eBook Packages: Springer Book Archive